Quinolones in 2005: an update

F. Van Bambeke[1], J.-M. Michot[1], J. Van Eldere[2] and P. M. Tulkens[1]

[1]Unit of Cellular and Molecular Pharmacology, Catholic University of Louvain, Brussels and
[2]Department of Microbiology and Immunology, Rega Institute and Centre for Molecular Diagnostics, University Hospital, Catholic University of Leuven, Louvain, Belgium

ABSTRACT

Quinolones are one of the largest classes of antimicrobial agents used worldwide. This review considers the quinolones that are available currently and used widely in Europe (norfoxacin, ciprofloxacin, ofloxacin, levofloxacin and moxifloxacin) within their historical perspective, while trying to position them in the context of recent and possible future advances based on an understanding of: (1) their chemical structures and how these impact on activity and toxicity; (2) resistance mechanisms (mutations in target genes, efflux pumps); (3) their pharmacodynamic properties (AUC/MIC and C_{max}/MIC ratios; mutant prevention concentration and mutant selection window); and (4) epidemiological considerations (risk of emergence of resistance, clonal spread). Their main indications are examined in relation to their advantages and drawbacks. Overall, it is concluded that these important agents should be used in an educated fashion, based on a careful balance between their ease of use and efficacy vs. the risk of emerging resistance and toxicity. However, there is now substantial evidence to support use of the most potent drug at the appropriate dose whenever this is required.

Keywords Ciprofloxacin, pharmacodynamics, quinolones, resistance, review, toxicity

INTRODUCTION

With more than 800 million patients treated, quinolones are currently one of the main classes of agent in the antimicrobial armamentarium, with therapeutic indications having evolved from urinary tract infections in the early 1970s to infections of almost all body compartments at the present time. This achievement has been made possible by a clear understanding of the structure–activity relationships for this class of molecules [1,2]. This knowledge has led to an intense effort to synthesise new derivatives with a broader spectrum, higher intrinsic activity, and an improved pharmacokinetic (PK) profile (all attributes that were meant to yield better clinical outcomes), and the ensuing publication of a very large amount of chemical, microbiological and clinical data. It has been estimated that more than 10 000 new molecules have been synthesised in

this class; a PubMed search reveals *c.* 2000 primary papers and 600 reviews on the topic of quinolones for the period 1985–2005. However, these efforts were compromised by the emergence of resistance [3–7] and, for some of these molecules, unacceptable side-effects [8]. Many authors [9–15] have examined quinolones in terms of their development, susceptibility of clinical isolates, clinical efficacy in specific indications, positioning in guidelines, or the profile of specific molecules. While these drugs originally appeared almost as a panacea, and promised a bright future [16,17], the scientific community now tends to call for cautious, or even restricted, use of these agents [18–21] for ecological reasons, to avoid the dissemination of resistance, and to control antibiotic overuse and misuse (see [22,23] for two practical approaches in Europe). Together with considerations based on local costs and the availability of generic agents, this has resulted in large variations in quinolone sales among countries, especially in Europe [24].

This review presents an historical perspective of the quinolones, and attempts to reposition

Corresponding author and reprint requests: F. Van Bambeke, UCL 7370 avenue E. Mounier 73, B-1200 Brussels, Belgium
E-mail: vanbambeke@facm.ucl.ac.be

them in the context of recent and possible future advances based on an understanding of resistance mechanisms, pharmacodynamic (PD) concepts, and a critical appraisal of the advantages and drawbacks of these compounds when used for their main therapeutic indications.

ORIGIN AND STRUCTURE–ACTIVITY RELATIONSHIPS

Discovered in 1962 as a by-product of anti-malarial research [25], nalidixic acid is the parent compound of the quinolone class of antibiotics. The use of nalidixic acid was originally limited because of its narrow spectrum, low serum levels, and toxicity issues, but it regained attention in the 1980s for the treatment of diarrhoea and urinary tract infections following the development of resistance in *Shigella* and *Escherichia coli* to other classes of antibiotics used at that time. This marked the beginning of an active campaign of chemical synthesis to refine structure–activity relationships, with the aim of improving activity while optimising pharmacokinetics and reducing toxicity and drug interactions (Fig. 1; see [1,2,26] for reviews on structure–activity and structure–toxicity relationships). Accordingly, many quino-lone molecules have been patented (key examples are shown in Fig. 2), but only a few have been commercialised and reached the clinic; indeed, the attrition rate of > 999/1000 molecules created illustrates clearly the unpredictable and risky nature of pharmaceutical research.

Quinolones available for clinical use have been classified into four generations, mainly on the basis of their spectrum of activity [27]. Following the lead of flumequine, the second generation of quinolones had the major feature of a fluorine substituent (F) at position 6 (hence the name of fluoroquinolones often given to the whole class), which increased activity markedly. These early compounds were most potent against Gram-negative organisms; thus their activity against *Streptococcus pneumoniae* was too marginal to warrant clear indications for use in the treatment of respiratory tract infections, and the emergence of resistance soon reduced their potential against *Staphylococcus aureus*. Of these compounds, ciprofloxacin and ofloxacin are the most widely used today, with ciprofloxacin still being the most active against *Pseudomonas aeruginosa*. Ofloxacin is a chiral molecule with only the S-(–) isomer as an active component. The latter has been commer-cialised as levofloxacin, which is, by its nature, twice as active as ofloxacin per unit of mass, but with no intrinsic change in its spectrum. The other members of the second generation, sparfloxacin and grepafloxacin, must be considered separately, since their substituent at position 5 and the bulki-ness of their substituent at position 7 improved their activity significantly against *Strep. pneumo-niae*. However, both of these agents were soon withdrawn or restricted for toxicological reasons.

Further improvement in activity against Gram-positive bacteria, together with significant anti-anaerobe activity, was seen with the third-generation molecules, caused by the presence of an alkyl-substituted piperazine or pyrrolidine at position 7, and of a methoxy at position 8. In this class, trovafloxacin (a naphthyridone), although not an 8-methoxyquinolone, was one of the most active compounds, and had the broadest spec-trum when registered, but was soon restricted to the treatment of severe infections in the USA, and was withdrawn in Europe, because of rare cases of hepatotoxicity. The most recent available member of this group is gemifloxacin (also a naphthyri-done), which possesses a very large spectrum of activity, including some anaerobes, but gemi-floxacin is currently approved only in Korea, New Zealand, the USA and Canada.

These extensive research efforts have enabled a better definition of the structural moieties or elements around the basic pharmacophore that offer the best combination of clinical efficacy, reduced resistance selection, and safety. These elements include a cyclopropyl at position 1, a methoxy at position 8, a (substituted) pyrrolidine or substituted piperazine at position 7, and a fluor substituent at position 6. Optimising all other substituents has permitted the removal of the fluorine atom at position 6 (which has been claimed to be involved in genotoxicity and central nervous system defects [2] possibly involved in genotoxicity), giving rise to the fourth generation of quinolones, termed des-fluoroquinolones, with garenoxacin as its first representative. The future of this molecule is, however, uncertain.

MECHANISM OF ACTION AND SPECTRUM OF ACTIVITY

Fig. 3 shows the cumulative distribution of susceptibilities of the five fluoroquinolones with

generation	drug [orig. ref./patent]]	X	R_8	R_1	R_5	R_6	R_7
1	nalidixic acid [283;284]	N		-CH₂-CH₃	H	H	-CH₃
2a	**norfloxacin** [285-287	C	H	-CH₂-CH₃	H	F	
	pefloxacin [288;289]	C	H	-CH₂-CH₃	H	F	
	lomefloxacin [290;291]	C	F	-CH₂-CH₃	H	F	
	ciprofloxacin [292-294]	C	H		H	F	
	ofloxacin [295;296]				H	F	
	levofloxacin [297;298]				H	F	
2b	*sparfloxacin* [299;300]	C	F		-NH₂	F	
	grepafloxacin [301;302]	C	H		-CH₃	F	
3a	gatifloxacin [303;304]	C	-O-CH₃		H	F	
	trovafloxacin [305;306]	N			H	F	
	moxifloxacin [307;308]	C	-O-CH₃		H	F	
3b	gemifloxacin [309;310]	N			H	F	
4	garenoxacin [311;312]	C	-O-CHF₂		H	H	

Fig. 1. Pharmacophore and structures of the main quinolones that have been approved for human use. Names in bold refer to compounds in large-scale clinical use in Europe. Names in italic refer to compounds for which commercialisation has been suspended or severely reduced because of side-effects and/or a decision of their registration holders (the development of garenoxacin in Europe and North America is at present uncertain).

Fig. 2. Structure–property relationships in quinolones. The central part of the molecule refers to the pharmacophore shown in Fig. 1.

Fig. 3. Cumulative MIC distributions for wild-type populations of four major pathogens (redrawn from data obtained and made publicly available by the European Committee on Antimicrobial Susceptibility Testing (EUCAST); see http://www.eucast.org). Each reference distribution is the result of aggregated MIC data obtained from publications in international journals, national breakpoint committees, reference laboratories, international antimicrobial surveillance systems, such as EARSS (http://www.earss.rivm.nl) or those sponsored by pharmaceutical companies, and antimicrobial susceptibility testing device manufacturers. As such, the data are meant to represent the natural variability in the susceptibility of organisms without specific, acquired resistance mechanisms to the corresponding drugs.

the current largest clinical usage in Europe with respect to wild-type populations of four major pathogens, i.e., in the absence of acquired resistance. These data support the structure–activity relationships discussed above, and confirm that ciprofloxacin is the most active agent against Gram-negative organisms, that moxifloxacin is preferentially active against Gram-positive organisms, that ofloxacin and levofloxacin show intermediate activity (with the two-fold difference in intrinsic activity for levofloxacin mentioned above), and that norfloxacin is an intrinsically weak fluoroquinolone against Gram-positive organisms.

As described previously [28–31], the activity of quinolones stems primarily from the formation of ternary complexes between DNA and type II topoisomerases, namely DNA gyrase and topoisomerase IV, two enzymes that play a critical role in the supercoiling of DNA [32–34]. The rapid bactericidal effect of fluoroquinolones is thought to result from the release of DNA ends, which are thought to induce bacterial apoptosis [35].

Both topoisomerase enzymes are essential for bacterial growth, but they cannot complement one another. Several studies have highlighted substantial variations in the in-vitro inhibitory concentrations for DNA gyrase and topoisomerase IV, depending on both the bacterial species and the molecule being studied (Table 1). These data, which are roughly consistent with MIC

Table 1. Range of inhibitory concentrations of 5-fluoroquinolones for DNA gyrase and topoisomerase IV isolated from different bacterial species [36,52,236–249]

| | IC_{50} (mg/L) | | | | | | | |
| | *Streptococcus pneumoniae* | | *Staphylococcus aureus* | | *Escherichia coli* | | *Pseudomonas aeruginosa* | |
Drug	DNA gyrase	Topo IV	DNA gyrase	Topo IV	DNA gyrase	Topo IV	DNA gyrase	Topo IV
Norfloxacin	582	35	55.5 to > 100	10–12	1.5	7		
Ciprofloxacin	80–138	5–7	13.5–25	4–6	< 0.75	2	0.5	4
Ofloxacin[a]	88	10	12–19	10–23	< 0.75	12	1.5	9.5
Moxifloxacin	22	6	3.5	8				
Gemifloxacin	5–10	2–5						

[a]Values for levofloxacin (active isomer of ofloxacin) are half of these values.
Topo IV, topoisomerase IV.

values and data obtained from analysis of resistant mutants, confirm that DNA gyrase is the preferred target of fluoroquinolones in Gram-negative bacteria. The situation is more complex in Gram-positive bacteria. For example, the IC_{50} ratio in *Strep. pneumoniae* is significantly different between ciprofloxacin and ofloxacin (or sparfloxacin) and moxifloxacin (or gemifloxacin). Taking into account the fact that equivalence in target preference is denoted by an IC_{50} ratio of 2–3, and the fact that inhibition of DNA gyrase is probably more lethal to the cell than inhibition of topoisomerase IV, this could explain the observation that gyrase becomes the preferred target in clinical isolates with resistance mutations.

Although the structural features responsible for the interaction of fluoroquinolones with the binding sites on DNA gyrase or topoisomerase IV are not yet unravelled fully, the design of derivatives that target both enzymes selectively has been proposed [36–39]. A useful development in that direction has been the introduction of a methoxy group (such as in moxifloxacin and gatifloxacin [40], where this group actually replaced a chlorine that had similar properties with respect to activity, but caused phototoxicity).

RESISTANCE

Bacterial resistance to quinolones can essentially develop through two main mechanisms, namely a decrease in the intrabacterial concentration of a drug, or alterations in a drug's target enzymes. While the former mechanism permits immediate survival and is largely inducible, the second is stable and is disseminated more easily. It will therefore be discussed first.

Target site alteration results from mutations in the chromosomal genes encoding the DNA gyrase and topoisomerase IV. These genes are commonly called *gyrA* and *gyrB*, and *parC* and *parE*, respectively (*grlA* and *grlB* in *Staph. aureus*). Such mutations probably result from transcription errors during chromosome replication, and occur at rates as high as 1 in 10^6 to 1 in 10^9 in wild-type bacteria [41]. In *Strep. pneumoniae*, another mechanism that might also lead to fluoroquinolone resistance mutations is horizontal gene transfer [42,43] from viridans group streptoccoci. Mutations tend to cluster in a region called the 'quinolone resistance-determining region' which, in the resulting GyrA protein, corresponds to the

domain that is bound to DNA during enzyme activity [44]. These mutations result in reduced drug affinity [45,46].

Phenotypic resistance arises in a stepwise fashion as a result of accumulating mutations. First-step mutations occur commonly in the primary or preferred drug target enzyme (thus more often in *gyrA* for Gram-negative, and more often in *parC* for Gram-positive organisms; mutations in *parE* mutations are uncommon). However, in *Strep. pneumoniae*, first-step mutants selected with ciprofloxacin tend to be *parC* mutants, whereas those selected with moxifloxacin (or gatifloxacin and sparfloxacin) tend to be *gyrA* mutants, reflecting a different preferred target of these fluoroquinolones for this species [35,47–49]. Mutation of *gyrA* has been described for *Chlamydia pneumoniae* following serial cultures with increasing moxifloxacin concentrations [50]. Second-step resistance mutations may then accumulate in the secondary drug target enzymes and will further affect quinolone resistance [51].

The precise effect of mutations in the gyrase and topoisomerase IV genes on the resistance phenotype may differ between bacterial species [52], but depends also on the precise gene involved and which specific quinolone is used. While some mutations in the primary target might be sufficient for acquisition of detectable resistance, this is not always the case. Thus, first-step *parC* mutations in *Staph. aureus* are associated with low-level resistance, and highly resistant clinical isolates usually possess several mutations [53–55]. In studies involving well-defined single-step mutants, each mutation in the quinolone resistance-determining region of gyrase or topoisomerase genes usually decreased susceptibility 4–8-fold [56–58]. Although second-step mutations in the secondary targets tend, in general, to have less impact on the resistance phenotype, they increase the resistance level further, but the effect of each mutation on the resistance level to different quinolones may vary. Thus, a pattern of cross-resistance between different molecules may develop, whereby parallel, simultaneous increases in MICs are observed. Conversely, dissociated resistance may occur in which there is no significant change in MIC values for some molecules, but significant increases for others [41,51,59] (Fig. 4). These observations are obviously important in that they may favour the use of compounds that display this type of dissociated

Fig. 4. Cross-resistance and dissociated resistance in quinolones. Q_A and Q_B illustrate a situation of cross-resistance: although the initial susceptibility of the strain may be different for molecules A and B, mutations in the target enzymes lead to similar changes in the susceptibility to both drugs. Q_C illustrates a situation of dissociated resistance: the susceptibility to molecule C does not change in spite of the acquisition of a first mutation, and will increase only upon acquisition of a second mutation.

resistance, select mutants with less impact on MIC values, or display lower frequencies of selection of resistance mutations. In this respect, a methoxy in position 8 could also be important, since it has been shown to reduce the probability of selection of resistant mutants [60–62].

The second main mechanism leading to quinolone resistance is associated with a decrease in their intrabacterial concentrations. Changes in the outer-membrane, including altered outer-membrane porins (OmpF) leading to reduced entry of antibiotics, have been reported previously with Gram-negative bacteria [63,64]. The resulting changes in quinolone susceptibility were often accompanied by reduced susceptibility to other classes of antibiotics (mainly carbapenems). Resistance in such mutants is usually of a relatively low level, as entry is not prevented completely; so clinically significant resistance often occurs in combination with other resistance mechanisms. However, because the mutations identified in these strains cause pleiotropic alterations, the possibility that resistance in these mutants is actually caused by increased efflux, which was only recognised in the mid-1980s [65], cannot be excluded. An increasingly large number of reports have now implicated efflux as a major mechanism of antibiotic resistance [66]. Efflux pumps appear to be ubiquitous, and are probably essential in the general physiology of bacteria [67]. They can be encoded either by chromosomal genes or by genes associated with mobile elements. When expressed constitutively, these genes are probably responsible for many cases of so-called 'intrinsic resistance', and bacteria lacking efflux pumps have even been proposed as ideal organisms to screen for new antibiotics because of their hypersensitivity to a large number of antimicrobial agents [68]. When induced or activated, they usually cause low-to-moderate levels of phenotypic resistance to fluoroquinolones [46], which can become clinically relevant when combined with mutations in the target enzymes. In some cases, however, efflux-pump systems can themselves be responsible for clinically relevant resistance [69–72]. Perhaps more importantly, efflux favours the emergence of resistant mutants because it enables bacteria to survive in the presence of sub-optimal concentrations of antibiotics [73]. Increasing the bulkiness of the substituent at position 7 contributes to a reduction in the transport of quinolones by efflux proteins of bacteria [74], which explains the low efflux rate of moxifloxacin and garenoxacin in *Strep. pneumoniae* [74–77]. Efflux-mediated resistance has now been described in pneumococci (PmrA) [78,79], staphylococci (NorA) [80,81], anaerobes [82] and Gram-negative bacteria [73,83,84]. In the last of these groups, efflux systems usually have broad substrate specificity, recognising several classes of chemically unrelated molecules and yielding a multiresistance phenotype.

Finally, plasmid-mediated resistance to quinolones has been reported in *Klebsiella pneumoniae* and in *E. coli* [85,86]. The plasmid encodes a *qnr* gene product (218 amino-acids) that lowers gyrase binding to DNA [87,88], but bacteria carrying the plasmid still need additional deficiencies in outer-membrane proteins to display clinically meaningful resistance [87,89]. So far, the prevalence of the *qnr* gene is rare, although reports from China suggest that a high local prevalence is possible [86]. The *qnr* gene has been observed recently in a single isolate of *E. coli* from Europe, carried on a conjugative plasmid conferring resistance to quinolones, most β-lactams

except carbapenems, most aminoglycosides, sulphonamides, rifampicin, trimethoprim and chloramphenicol [90].

PHARMACOKINETICS AND PHARMACODYNAMICS

Most quinolones show excellent bioavailability, which makes them ideal for ambulatory patients and for intravenous-to-oral antibiotic switches in hospitalised patients [91]. They are also characterised by excellent penetration into most tissues and body fluids (consistent with a distribution volume of *c*. 1–4 L/kg), but their serum levels are usually low, especially when fractionated dosing schedules are used. Although barely greater than the breakpoints of 2 mg/L proposed originally [92], these levels were nevertheless considered to be sufficient at the time of registration of the second-generation quinolones. Early studies showed that quinolones, like aminoglycosides but in contrast to β-lactams, work mainly in a concentration-dependent manner [93] and exert a marked post-antibiotic effect [94], although this is not consistent across all species. Studies in neutropenic animals reinforced this conclusion by demonstrating that unfractionated schedules produced a better survival rate [95], provided that a C_{max}/MIC ratio of >10 could be reached (see [96] for a definition of the various PK and PD parameters of antimicrobial agents and their meaning). At lower values, the $AUC_{24 h}$/MIC ratio became more predictive, perhaps because of the decreased rate of bacterial killing.

At about the same time, clinicians noticed unacceptable rates of failure and emergence of resistance to ciprofloxacin when treating infections caused by organisms with an MIC close to the breakpoints with the commonly used low dosages (2 × 200 mg) [97–99]. This led to the first, large-scale clinical study aimed at defining the PD parameters which were predictors of efficacy [100]. Univariate analysis showed that the $AUC_{24 h}$/MIC ratio (> 125) linked best with both the clinical and microbiological outcomes, and that a C_{max}/MIC ratio of < 4 was associated significantly with a sub-optimal outcome. However, the use of twice- and three-times-daily dosing schedules did not allow analysis of the benefits of high peak concentrations, since these were infrequent. A subsequent clinical study of levofloxacin with community-acquired pneumonia [101] stressed the importance of the C_{max}/MIC ratio (if > 12.2). However, in this study, as in that of Forrest *et al.* [100] and most other clinical studies, the lack of variability in dosing schedules made C_{max} and AUC covariates, so that their relative roles could not be distinguished. Taking into account this limitation, and realising that high C_{max}/MIC ratios are difficult to obtain with second-generation quinolones and organisms with elevated MICs, most investigators and drug companies have now adopted the $AUC_{24 h}$/MIC ratio (using preferably free levels) as a practical predictive parameter for efficacy. Indeed, in limited trials this parameter appeared to be linked strongly to clinical outcome and, in experimental studies, was largely independent of the dosing interval, the fluoroquinolone used, the animal species and the site of infection [102–104]. The question remaining unanswered is the minimal value of this parameter, with a value of 25 appearing sufficient for less severe infections and/or immunocompetent hosts, but with a value of ≥100 appearing necessary for severe infections and/or immunocompromised hosts [105].

Perhaps the true picture comes from a close examination of both the experimental studies and the clinical data. The former show that required levels of drug exposure depend critically upon the desired effect [106]. For instance, moving from an EC_{50} to an EC_{99} effect with in-vitro dynamic models requires an increase of about ten-fold in AUC/MIC ratios [107]. In animals, this ratio must be increased up to five-fold to move from a static effect and a $2 × \log_{10}$ kill in immunocompetent animals, and up to about three-fold for a static effect between neutropenic and non-neutropenic animals [108]. The clinical data actually point to the same conclusion by showing that an $AUC_{24 h}$/MIC ratio of 125 will yield efficacy by day 7, but that higher values (> 250) will produce faster bacterial eradication [109]. Therefore, time-related events must also be taken into consideration. The available data can therefore be interpreted as meaning that aiming at minimal values may be quite dangerous, given the possibility of large variability in individual PK parameters [110], the often imprecise character of the MIC determinations [111], and the uncertain immunological status of many patients. Table 2 proposes conservative $AUC_{24 h}$/MIC-based limits of sensitivities (free drug concentrations have been used, since bound fluoroquinolones do not participate

Table 2. Pharmacokinetic parameters used for proposing PK/PD based limits of sensitivity and conditions favouring the prevention of emergence of resistance for most common organisms and systemic infections, together with the breakpoints set by European and American ad-hoc organisations

Drug	Typical daily dosage[a]	Typical PK values		Proposed PK/PD upper limit		Breakpoints (mg/L)[d]	
		C_{max} in mg/L total/free (dose)	$AUC_{24 h}$ (mg × h/L) total/free	Efficacy[b]	Prevention of resistance[c]	EUCAST (S-R)	NCCLS (S-I-R)
Norfloxacin	800 mg	1.4/1.1 (400 mg PO)	14/11	0.1–0.4	0.1	≤ 0.5 to > 1[e]	≤ 4–8 > 16[j]
Ciprofloxacin	1000 mg	2.5/1.75 (500 mg PO)	24/18	0.2–0.8	0.2	≤ 0.5 to > 1[f] (≤ 0.125 to > 2)[g]	≤ 2–2 > 4[k]
Ofloxacin	400 mg	4/3 (400 mg PO)	40/30	0.3–0.9	0.4	≤ 0.5 to > 1[f] (≤ 0.125 to > 4)[g]	≤ 2–4 > 8[l]
Levofloxacin	500 mg	4/2.8 (500 mg PO)	40/28	0.3–0.9	0.3	≤ 1 to > 2[f] (≤ 2 to > 2)[h]	≤ 2–4 > 8[l]
Moxifloxacin	400 mg	3.1/1.8 (400 mg PO)	35/21	0.2–0.7	0.2	≤ 0.5 to > 1)[e] (≤ 5 to > 0.5)[i]	≤ 1–4 > 4[m]

EUCAST, European Committee on Antimicrobial Susceptibility Testing (http://www.eucast.org) [241].
NCCLS, National Committee for Clinical Laboratory Standards (Clinical and Laboratory Standards Institute) (http://www.nccls.org).
S, susceptible; I, intermediately resistant; R, resistant.
[a]In patients with no gross abnormality of the excretory functions, and for most common tissue-based infections (thus excluding simple cystitis); based on recent typical 'Summary of Product Characteristics' (SPC, or 'labelling' in Europe). Recent guidelines, and SPC in some countries, suggest higher dosages for ciprofloxacin (up to 1200 mg/day), ofloxacin (up to 800 mg/day), and levofloxacin (750–1000 mg/day). Because the pharmacokinetics of registered quinolones are linear with respect to doses (within the limits of the agents registered), adaptation of the figures of C_{max} and $AUC_{24 h}$ for doses other than those shown here can be done by simple extra- or intrapolation.
[b]Based on a free $AUC_{24 h}$/MIC ratio ranging from 30 (pneumococcal infection/immunocompetent host) to 100 (Gram-negative infection/immunoimpaired host); see discussion in text in support of these values as average means for free concentrations.
[c]Based on a minimal C_{max}/MIC ratio of 10, considered to encompass the 'mutant prevention concentration' of most susceptible isolates (see text for discussion). Application of this criterion will also meet the requirement for larger $AUC_{24 h}$/MIC ratios than needed for efficacy.
[d]For organisms within the main indications.
[e]Enterobacteriaceae only (*Pseudomonas* is considered to be non-susceptible).
[f]For most Gram-negative organisms, including *Pseudomonas*; 1 for *Staph. aureus* with high-dose therapy.
[g]Values in parentheses refer to *Streptococcus pneumoniae*, where the wild-type population is not considered susceptible to ciprofloxacin or ofloxacin, and is therefore categorised globally as 'intermediate'.
[h]For *Strep. pneumoniae* and levofloxacin, the breakpoint was increased to 2 to avoid dividing the wild-type population (see [242] for a typical example from France), but this breakpoint relates to high dose therapy.
[i]For *Strep. pneumoniae*, *Haemophilus influenzae* and *Moraxella catarrhalis*.
[j]Enterobacteriaceae and *P. aeruginosa*.
[k]*Staphylococcus aureus*, Enterobacteriaceae and *P. aeruginosa*.
[l]*Strep. pneumoniae*, *Staph. aureus*, Enterobacteriaceae and *P. aeruginosa*.
[m]*Strep. pneumoniae*.

directly in activity [112,113]). However, the C_{max}/MIC ratio may be critical in preventing the emergence of resistance (see below), and quinolones with a higher C_{max} are probably desirable in this context.

IMPLICATIONS OF PK/PD FOR THE PREVENTION OF RESISTANCE

The recognition of the relatively fast emergence of resistance to quinolones has only recently triggered PK/PD research aimed at reducing this risk. Yet in-vitro studies and animal models, and, to some extent, clinical investigations concur in indicating that low $AUC_{24 h}$/MIC ratios, even if clinically effective, will be conducive to the selection of resistant mutants [114–119]. A more fundamental approach has probably been taken by developing a novel in-vitro measure of quinolone potency called the 'mutant prevention concentration' (MPC). Described originally for *Mycobacterium bovis* [60], the MPC is the

concentration that prevents the growth of the next-step mutant of a bacterial strain. It essentially defines the concentration threshold that would require a bacterium to simultaneously acquire two resistance mutations for growth in the presence of that specific drug. Determination is made by plating at least 10^{10} bacteria in the presence of increasing concentrations of a quinolone, and determining the concentration at which no growth occurs [120]. A concentration of 10^{10} CFU was chosen to detect mutations occurring at frequencies of 10^{-7}–10^{-9}, as well as to mimic the typical bacterial load and population heterogeneity at the site of infection. This method has now been applied to several bacterial species and different quinolones [121–128]. The MPC provides a numerical threshold that might be used to severely restrict, if not prevent, the selection of resistance during therapy [129], and can thereby suggest minimum serum concentrations to be attained [130]. Third-generation fluoroquinolones (gatifloxacin, gemifloxacin,

moxifloxacin) usually display lower MPC values for isolates of *Strep. pneumoniae* than do older fluoroquinolones, although the situation may be less favourable with organisms already carrying one mutation [131–133]. For *P. aeruginosa*, ciprofloxacin has a lower MPC than levofloxacin [134]. These observations are concurrent with the observed stepwise 4–8-fold increase in MICs that results from accumulating mutations in the topo-isomerase genes, and the observation that the higher the ratio of C_{max} over MIC, the better the outcome [135]. Studies on the MPC have led to the development of the concept of the 'mutant selection window', which states that resistant mutants are best selected at antibiotic concentrations above the MIC (a selection pressure being necessary), but below the MPC [129]. This concept has now been demonstrated *in vitro* for *Staph. aureus* [124] and *Strep. pneumoniae* [116].

Two practical difficulties face the clinician wishing to use the MPC as a useful target concentration. First, apart from a natural variation in MPC values between genetically different strains from the same species, the unknown status of resistance mutations in the strain makes predictions difficult, as outlined above. Second, little is known about the time during which the bacteria must be exposed to concentrations above the MPC to effectively prevent the selection of resistant mutants. Experimental studies show that selection will occur when the quinolone concentration remains inside the mutant selection window for >20% of the dosing interval, which will most often be the case for patients with an $AUC_{24\,h}$/MIC ratio of 30–60 [116]. Therefore, the available data can be interpreted as meaning that quinolones should be chosen, and their dosages and schedules selected, to reach at least a C_{max}/MIC ratio of 10. This will increase the probability of maintaining the concentration above the mutant selection window for a large proportion of the dosing interval. This concept has been included in Table 2 (prevention of resistance).

EPIDEMIOLOGY OF RESISTANCE DEVELOPMENT

The notoriously fast development of resistance to second-generation quinolones has quickly removed the effectiveness of compounds such as pefloxacin against both Gram-negative and Gram-positive organisms. The situation has been more mixed for ciprofloxacin and ofloxacin with respect to Gram-negative organisms. While both of these quinolones still remain as first choices in many therapeutic guidelines, quite alarming levels of resistance in *P. aeruginosa* are now reported worldwide and in specific settings [6,7,136–143]. However, large variations in resistance levels exist that are not explained easily (see [144] for a typical example in Europe), although the volume and type of fluoroquinolone used, both in the hospital and the surrounding community, are among the determinants [145–147]. The correct approach probably requires close surveillance of susceptibilities at the local level, and the formulation of appropriate antibiotic policies that should restrict unnecessary use, in combination with appropriate PK/PD-based dosing when needed, and more systematic MIC measurements. Collecting MIC data appears essential; indeed Table 2 illustrates that resistance breakpoints are set at values which are not supported by recent PK/PD data, not to mention optimal efficacy. In apparent contrast, there are optimistic global reports concerning *E. coli* [139,148–151], albeit with local observations that often point to much higher rates of resistance, perhaps related to the site of infection and the status of the patient. Here also, the answer may lie in closer surveillance and application of PK/PD principles in all cases for which the outcome might become uncertain.

The picture is quite different for levofloxacin (and third-generation quinolones) against *Strep. pneumoniae*. Resistance has remained low [152] and increases only slowly [153,154]. In this context, the alarming increase in ciprofloxacin resistance observed between 1988 and 1997 in Canada [155] should be considered atypical, as it results from inappropriate use of ciprofloxacin for the treatment of community-acquired respiratory tract infections in this country. There is also one well-known exception in Hong Kong [156], which retrospective analysis suggests was associated with the pan-regional dissemination of a specific fluoroquinolone-resistant variant, Hong Kong (23F)-1, perhaps triggered by low doses used in the treated population of patients with chronic obstructive pulmonary disease [157]. This is of interest when considering the extensive use worldwide of older quinolones for indications other than respiratory tract infections, since, because of the weak anti-streptococcal activity of these agents, exposure of commensal streptococci

to insufficient concentrations for a lengthy period of time might be anticipated. However, in contrast to macrolides and penicillin, for which the rates of resistance and/or decreased susceptibilities are much higher, quinolones have not been used in children, who may constitute a major reservoir for resistant streptococci, as they are prescribed a large proportion of the total human antibiotic consumption. Recent data suggesting decreased susceptibility of *Strep. pneumoniae* to levofloxacin in the USA in relation to its local use [158], coupled with reports of clinical failures [159] and recent trends towards decreased susceptibility of European isolates to ciprofloxacin [160], indicate a need for close surveillance and the formulation of global restrictive prescribing policies.

There is also considerable evidence for clonal spread [161], although polyclonal spread has been seen in Japan [162]. Since resistance to quinolones is the result of the accumulation of spontaneous mutations that can occur rapidly in treated patients [159], it seems logical that resistant mutants would belong to many different genotypes. If this were indeed the principal driving force for resistance, a gradual increase in resistance rates following the gradual emergence and selection of resistant mutants in a wide range of different genotypes would be expected, more or less concurrent with the total use of quinolones. However, recent data support an important role for a small number of highly epidemic bacterial clones in the spread and overall rate of quinolone resistance [163]. This has also been observed for fluoroquinolone-resistant methicillin-resistant *Staph. aureus* [164] and gonococci [164].

Finally, target mutations and overexpression of efflux mechanisms have often been associated with significant fitness cost, resulting in a reduced growth rate and/or virulence in the absence of antibiotic challenge. However, compensatory mutations may partly or fully restore the function impaired by the resistance mutation [165]; indeed, evidence for an enhanced in-vivo fitness of resistant strains in the absence of antibiotic pressure has been presented for *Campylobacter jejuni* [166]. The biological price that bacteria pay for quinolone resistance appears therefore to be limited [51], and, as a consequence, the emergence of resistant strains could be easy, leading to a rapid increase in resistance rates that will depend not solely on total quinolone use, but also on all the other factors that drive the spread of epidemic clones. For *Strep.*

pneumoniae in particular, there are fears that use of quinolones for indications that carry a higher risk of multiresistant epidemic clones (e.g., infections in children, and chronic respiratory infections in elderly patients) could impact significantly on resistance rates. A first case of failure of oral levofloxacin treatment for community-acquired pneumonia caused by *Haemophilus influenzae* has been reported, with step-by-step mutations in DNA gyrase and topoisomerase IV [167]; this type of mutant can be obtained easily in the laboratory with ciprofloxacin by stepwise selection [128]. Again, these concerns can be addressed by the implementation of closer and improved surveillance methods (including not only serotyping and MIC determination, but also surveillance of specific mutations and efflux mechanisms), a decrease in the non-justifiable use of quinolones, and closer attention to PK/PD considerations when the use of an antibiotic is deemed essential. This is probably critical, as current breakpoints fail to identify most *Strep. pneumoniae* isolates with only first-step mutations [168] or with efflux mechanisms.

TISSUE ACCUMULATION/DISTRIBUTION AND ITS MEANING

Much has been reported regarding the presence of fluoroquinolones in epithelial lining fluid and pulmonary tissues [19,169] in support of the use of fluoroquinolones for treating respiratory tract infections. However, the key question, unanswered so far, is whether tissue accumulation is necessary in such a highly vascularised tissue as lung, where most common pathogens are probably extracellular. Penetration in other less accessible tissues, such as bone or prostate, is probably more important and beneficial [170,171]. Penetration in cerebrospinal fluid is certainly critical, and explains the appropriateness of quinolones for the treatment of meningitis [172]. A key feature of quinolones is their ability to accumulate in polymorphonuclear leukocytes and macrophages, with cellular concentrations at equilibrium being 5–20-fold higher than extracellular concentrations [173,174]. Influx probably occurs by simple passive diffusion, although active transport has also been suggested [175,176]. However, neither the mechanism of accumulation nor the subcellular localisation are known with certainty; the bulk of cell-associated quinolone is found in the soluble

fraction of cell homogenates [174,177], but part of the drug could have access to other organelles [178].

Quinolones show activity in a large series of models of cells infected by bacteria sojourning in different subcellular compartments [179], such as *Listeria monocytogenes* (cytosol) [180], *Salmonella* spp. (phagosomes) [181], *Legionella pneumophila* (endoplasmic reticulum; phagolysosomes) [182], *Chlamydia* spp. (inclusions) [183,184], *Mycobacterium* spp. (endosomes) [185], or opportunistic intracellular species such as *Staph. aureus* [186] or *H. influenzae* [187]. The efficacy of quinolones against intracellular pathogens has been confirmed in the corresponding animal models of infection [188–192]. Clinical studies demonstrating their efficacy in human infections, such as in atypical pneumonia [193–195] or tuberculosis, are now being published, [196–198]. However, in-vitro models show that the intracellular activity of quinolones is markedly lower than would be anticipated from their level of accumulation [179].

Cell-associated quinolones are also subject to active efflux, mainly because of the activity of ABC transporters known to confer multiresistance, such as P-glycoprotein and 'multiple resistant protein'. This active efflux will cause reduced accumulation of antibiotic in phagocytic cells, and hence a reduction in intracellular activity [177]. The polarised location of the ABC transporters, organic cation transporter and the organic anion transporter [199] at the surface of epithelial cells bordering the intestine, liver, kidney and blood–brain barrier means that they can modulate the resorption, distribution and elimination of quinolones [200–202]. In some cases, transporters can also act in a concerted fashion and cooperate with the detoxification metabolism [203,204]. Efflux also plays a major role in the protection of the central nervous system, since an inverse relationship has been observed between the propensity of fluoroquinolones to induce seizures [205] and their rate of efflux from the central nervous system [206].

TOXICITY AND DRUG INTERACTIONS

Quinolone use is limited by a series of unwanted or adverse effects, most of which are mild but frequent, whereas others are rare but severe, and have caused the withdrawal of several class members (Table 3). Among these unwanted effects, some are class-related, meaning that they are not associated with any particular structural feature other than the general pharmacophore of the quinolones (Fig. 1). These effects are reported for all the molecules in the class, albeit with differences in incidence (e.g., gastrointestinal discomfort or arthralgia). Similarly, the ability of quinolones to form complexes with divalent and trivalent metal ions is linked intrinsically to the presence of the carboxylate function, and is therefore unavoidable. Oral bioavailability of quinolones can be retained by separating and delaying the administration of medications containing divalent and trivalent metal ions. Most of the other unwanted effects of quinolones are dependent on their substituents (Fig. 2), and are therefore specific to particular agents (Table 3).

The safety profile of quinolones is being updated constantly, since some of the adverse effects, such as cardiotoxicity, have recently attracted additional attention (see [207] for a review of current knowledge and an outline of strategies for early prediction during drug development), and use in large populations has revealed rare but severe toxicities, such as those observed with temafloxacin [208] and trovafloxacin [209], leading to a reassessment of registered compounds and a better appreciation of the true cost/benefit ratios. The introduction of new compounds will certainly be made more difficult because of these unforeseen events, and may lead to higher hurdles that must be passed before regulatory approvals are issued. One consequence for the commercialisation of new derivatives could be the initial restriction of new agents for indications or infections in those populations where the possible anticipated benefits are high (e.g., severe infections caused by organisms resistant to other classes of antibiotics), with broader use only when safety has been assessed satisfactorily. In parallel, proactive post-marketing surveillance studies [210] should be encouraged, since it is well-known that spontaneous reporting does not necessarily reveal the true impact of important unwanted side-effects.

CLINICAL USAGE: THE PROS AND THE CONS

Table 4 presents a summary of the main indications for the use of quinolones, together with the arguments for and against such use. Considering

Table 3. Main side-effects of quinolones that contribute to the limitation of their use, the frequency observed, and the populations at risk

Side-effect	Quinolone	Frequency	Population at risk
Genotoxicity			Pregnant women
Gastrointestinal effects (nausea, vomiting > diarrhea)	Fleroxacin, sparfloxacin, grepafloxacin[a]	> 10%	
	Others	2–8% [243]	
Skin reaction: phototoxicity	Sparfloxacin[a], fleroxacin[a], lomefloxacin[a], Bay 3118[a]	> 10% [244]	
	Others	< 2.5%	Cystic fibrosis [245]
Skin reactions: rash	Clinafloxacin[a]	4% [243]	
	Gemifloxacin	2.8% [246]	Young women
Chondrotoxicity	Pefloxacin[a]	14% [247]	Children, pregnant women
	Others	1.5% in children (ciprofloxacin [248])	
Tendinitis	Pefloxacin[a]	2.7% [249]	Elderly, especially if on corticosteroid therapy [250]
	> Levofloxacin/ofloxacin ≥ ciprofloxacin > Others [252,253]	0.4%	Athletes in training [251]
Minor CNS effects	Trovafloxacin	2–11% dizziness	Elderly [254]
Major CNS effects	Levofloxacin	0.026% confusion, alteration in mentation and affect [243]	Co-administration of NSAID or of inhibitors of CYP 450 [255]
	Fleroxacin[a] [256]	8% insomnia [257]	
Cardiovascular effects	Sparfloxacin[a] (9–28 ms)	2.9%	Female gender
	Grepafloxacin[a] (10 ms) Moxifloxacin (6 ms) Levofloxacin (3 ms)[b] Gatifloxacin (2.9 ms)		Co-administration of other drugs (prolonging QTc interval or inhibiting CYP 450 metabolism)
	Gemifloxacin (2.6 ms) [246,258–260]		Heart disease [254]
Minor hepatic effects (transaminase elevation)	Grepafloxacin	12–16% transaminase elevation [243]	
	Others	< 3% [261]	
Major hepatic effects	Trovafloxacin[a]	0.006% [243]	Treatment duration > 14 days [262]
Hypoglycaemia	Clinafloxacin[a] Gatifloxacin Levofloxacin (one fatal case [263]		Co-administration of oral hypoglycemic agents [264]
Haematological toxicity	Temofloxacin[a]	0.02% haemolysis, thrombocytopenia, renal failure [256]	
CYP 450 inhibition	Enoxacin[a], clinafloxacin[a] [256] > ciprofloxacin > lomefloxacin, ofloxacin > levofloxacin, sparfloxacin, gatifloxacin, moxifloxacin [262]		

[a]Side-effects have contributed to the withdrawal or limitation in use.
[b]Further studies have been requested from the manufacturer, as recent pharmacovigilance reports document a significant increase of the QTc interval, mainly in patients with concurrent medical conditions or other medications [243,265]; see also [266] for a recent study in the province of Varese, Italy, using prescription data on all incident users of several antibacterial and anti-arrhythmic drugs during the period July 1997 to December 1999.
NSAID, non-steroidal anti-inflammatory drug; CNS, central nervous system.

the general negative aspects, the argument presented most frequently is the risk for selection of resistance. As discussed above, acquisition of resistance to quinolones seems to be a relatively easy process, which is at variance with β-lactams, at least in pneumococci, where the process of acquisition of resistance has taken decades [211]. This is well-illustrated for *E. coli* [212,213], but, as described above, the dynamics of the phenomenon may differ from one species to another [144]. The fact that certain quinolones are orientated towards either Gram-positive or Gram-negative bacteria, rather than having a narrow spectrum, may actually trigger resistance in less susceptible organisms. Another consideration is that the absence of precise aetiological diagnostic tests for a number of common infections contributes, indirectly, to the overuse of quinolones as empirical drugs. As for other broad-spectrum antibiotics, the correct approach probably involves a more prudent use, based on a correct assessment of the necessity and knowledge of how to prescribe an antibiotic correctly in the first place [214–216].

The second, and less disputed, argument stems from known or suspected toxicities in specific populations, such as pregnant or breast-feeding women, children, or elderly patients with co-morbidities. Although children are an important target population with respect to infections that respond well to quinolones, such as diarrhoea or Gram-negative meningitis, the combined risks of toxicity and the rapid spread of resistance should contraindicate treating children with quinolones, with the possible exception of children with cystic fibrosis (for whom close monitoring of bacterial susceptibilities is essential) or life-threatening infections with organisms resistant to

Table 4. Use of quinolones in the clinics: pros and cons

Indication	Pros	Cons	References
All	PK/PD profile Once-daily administration (as compared to β-lactams)	Not recommended for children, or breast-feeding and pregnant women Prudent use in elderly because of increased risk of side-effects (co-morbidities, concurrent therapies) Risk of development of resistance	[233,267–269]
Respiratory tract infections			
Acute exacerbation of chronic bronchitis	Higher potency against *Haemophilus influenzae* than macrolides and ketolides		[14,19]
Community-acquired pneumonia	Easy switch to oral therapy Coverage of intracellular pathogens Polymicrobial infection		[14,19,270,271]
Cystic fibrosis	Oral administration	Joint complications more frequent in cystic fibrosis patients	[268]
Intensive care infections	High activity against Gram-negative bacteria, including *Pseudomonas aeruginosa* Lack of (or reduced) association with *Clostridium difficile* colitis No promotion of vancomycin resistance in enterococci	Increasing resistance in nosocomial pathogens	[272]
Skin and soft tissue infections	Concentration in skin and blister fluid equivalent to serum levels Coverage of Gram-positive and Gram-negative bacteria useful in polymicrobial infections	Too broad a spectrum for uncomplicated infections Resistance increasing in *Staphylococcus aureus*, including MRSA Combination with anti-anaerobic agent sometimes needed	[273,274]
Osteomyelitis	Oral route shortens hospital stay Penetration into bone	Combination with anti-anaerobic agent sometimes needed (e.g., for diabetics) Association with rifampicin for staphylococci	[275]
Abdominal infections	Adequate penetration in infected territories	Insufficient coverage of anaerobes	[276]
Intestinal infections	Good absorption, even in cases of diarrhoea, and high concentrations in stool	High resistance in *Campylobacter* and increasing resistance in *Salmonella* Limited use in children, who are at greatest risk of infection High cost in developing countries	[277]
Urinary tract infections	Elevated concentration in the urinary tract (including in the urine and in obstructed tractus) and in the prostate Little dosage adaptation if renal function impaired Easy switch to oral therapy	Increasing resistance	[278,279]
Sexually transmitted diseases	Intracellular penetration	Less effective than macrolides against *Chlamydia* Resistance widespread in *Neisseria gonorrhoeae* (with the possible exception of gemifloxacin)	[280,281]
Meningitis	Unique dose efficient in prophylaxis Penetration in CSF	Concentrations lower than in serum in non-inflamed meninges; use limited to very susceptible organisms (Gram-negative bacteria) Use restricted in the population most at risk (children)	[282]

MRSA, methicillin-resistant *Staphylococcus aureus*; CSF, cerebrospinal fluid.

other antibiotics. The situation may be more complex for elderly patients, for whom co-morbidities or co-medications clearly increase the risks (Table 4). However, these considerations should be weighed against the necessity to treat in the most effective way what are often recurrent polymicrobial infections, possibly involving organisms resistant to first-line antibiotics. Future studies should address these issues more carefully in order to better demonstrate the real

usefulness of quinolones in these populations [217].

The main advantages of quinolones are related to their PD (bactericidal activity) and PK properties. Their ease of use (oral route, once-a-day administration for some agents) is helpful, but compliance should not be the main issue for seriously ill patients. The easy switch to an oral therapeutic route can contribute to a reduction in the length of hospital stay, and has proven cost-effective in various settings and countries [218–223]. The latter argument might be quite compelling, since it can probably be applied for almost all types of infection in view of the wide distribution of quinolones in the body.

With regard to specific indications, the role of quinolones in urinary and digestive tract infections is not disputed [224,225]. Conversely, much debate exists in relation to their use in the treatment of abdominal and respiratory tract infections. The latter accounts for a variable extent of all quinolone usage among different countries (from almost no use to *c.* 50% of all quinolone consumption in the community), and the divergent guidelines published by scientific societies or national authorities [226] illustrate the difficulty of finding a consensus position in this area [21,227]. The advantages put forward concern the better activity of quinolones compared with macrolides against *H. influenzae* strains causing acute exacerbations of chronic bronchitis, the activity of a single drug against extracellular and intracellular pathogens, the quicker switch to the oral route, and the potential lower mortality for moxifloxacin in comparison with β-lactams for community-acquired pneumonia [228], although the registered dose of comparator used in this latter study may have been sub-optimal. However, most European guidelines have placed the so-called respiratory quinolones as second-line antibiotics only, with high-dose amoxycillin as the first choice (combined with clavulanic acid for a β-lactamase-producing organism). Such a recommendation is based on the assumption that early coverage of the so-called atypical organisms is not a priority, and that true resistance of pneumococci to β-lactams will remain low, despite continuous use [229]. The downside of the recommendation is the subsequent large-scale use of amoxycillin–clavulanic acid combinations (as seen from records of antibiotic prescriptions for respiratory tract infections), based on the premise that missing a

β-lactamase-producing organism may put the patient at risk.

With respect to abdominal infections, the main reason for limiting the use of quinolones is the level of resistance, which, as explained above, has become alarmingly high in certain settings. For instance, in addition to *E. coli*, *Bacteroides fragilis* has a more than doubled mean MIC of levofloxacin and moxifloxacin in the USA in the last 3 years, so that monotherapy with fluoroquinolones in intra-abdominal infections may become unwise in the absence of appropriate surveillance and aetiological diagnosis [230]. This may be a consequence of the previous widespread use of quinolones, which may have enriched first-step mutants in the intestinal tract [231], although efflux pump systems also contribute to resistance [232].

Besides the still-open question of whether or not to use a quinolone for a given indication, the other question of importance concerns the selection of a specific compound within the class. The answer here is not disputable, based on the PK/PD concepts and resistance mechanisms discussed above. The best advice would undoubtedly be to use the most potent drug at the appropriate dose [233] for the right infection, based on likely aetiology, with ciprofloxacin preferred for Enterobacteriaceae and *P. aeruginosa*, and moxifloxacin (or gemifloxacin where available) for streptococci.

CONCLUDING REMARKS

Fluoroquinolones were introduced with a fanfare in the mid-1980s as ciprofloxacin became the answer to many physicians' prayers for the treatment of Gram-negative infections, and as the spectre of multiresistant pneumococci made new agents more and more desirable. As long as these agents are used to treat the appropriate types of patients, and are not regarded by prescribers as the magic bullet, the effectiveness of the class will survive long into the present century. However, if they are dispensed with a lack of concern, then their day will conclude prematurely. As always, bacteria are smarter than humans, and both fundamental and very practical approaches are required to conserve antibiotics as useful agents and not as discoveries of the past [234,235]. Quinolones are no exception to this rule, which makes it essential that they are used in an educated fashion.

ACKNOWLEDGEMENTS

REFERENCES

1. Domagala JM. Structure–activity and structure–side-effect relationships for the quinolone antibacterials. *J Antimicrob Chemother* 1994; **33**: 685–706.

2. Domagala JM, Hagen SE. Structure–activity relationships of the quinolone antibacterials in the new millenium: some things change and some do not. In: Hooper DC, Rubinstein E, eds. *Quinolone antimicrobial agents*. Washington, DC: ASM Press, 2003; 3–18.

3. Quale J, Landman D, Ravishankar J, Flores C, Bratu S. *Streptococcus pneumoniae*, Brooklyn, New York: fluoroquinolone resistance at our doorstep. *Emerg Infect Dis* 2002; **8**: 594–597.

4. Ho PL. Decreased levofloxacin susceptibility in *Haemophilus influenzae* in children, Hong Kong. *Emerg Infect Dis* 2004; **10**: 1960–1962.

5. Pallares R, Fenoll A, Linares J. The epidemiology of antibiotic resistance in *Streptococcus pneumoniae* and the clinical relevance of resistance to cephalosporins, macrolides and quinolones. *Int J Antimicrob Agents* 2003; **22**(suppl 1): S15–S24.

6. Friedland I, Gallagher G, King T, Woods GL. Antimicrobial susceptibility patterns in *Pseudomonas aeruginosa*: data from a multicenter Intensive Care Unit Surveillance Study (ISS) in the United States. *J Chemother* 2004; **16**: 437–441.

7. Blandino G, Marchese A, Ardito F *et al.* Antimicrobial susceptibility profiles of *Pseudomonas aeruginosa* and *Staphylococcus aureus* isolated in Italy from patients with hospital-acquired infections. *Int J Antimicrob Agents* 2004; **24**: 515–518.

8. Sprandel KA, Rodvold KA. Safety and tolerability of fluoroquinolones. *Clin Cornerstone Suppl* 2003; **3**: S29–S36.

9. Andersson MI, MacGowan AP. Development of the quinolones. *J Antimicrob Chemother* 2003; **51**(suppl 1): 1–11.

10. Felmingham D. Comparative antimicrobial susceptibility of respiratory tract pathogens. *Chemotherapy* 2004; **50**(suppl 1): 3–10.

11. Cunha BA. Empiric therapy of community-acquired pneumonia: guidelines for the perplexed? *Chest* 2004; **125**: 1913–1919.

12. Jacobs MR. Fluoroquinolones as chemotherapeutics against mycobacterial infections. *Curr Pharm Des* 2004; **10**: 3213–3220.

13. Blondeau JM, Missaghi B. Gemifloxacin: a new fluoroquinolone. *Expert Opin Pharmacother* 2004; **5**: 1117–1152.

14. Blasi F, Tarsia P, Cosentini R, Cazzola M, Allegra L. Therapeutic potential of the new quinolones in the treatment of lower respiratory tract infections. *Expert Opin Invest Drugs* 2003; **12**: 1165–1177.

15. Hooper DC, Rubinstein E, eds. *Quinolone antimicrobial agents*. Washington, DC: ASM Press, 2003.

16. Schmidt J, Pollack CV. Antibiotic use in the emergency department. III. The quinolones, new beta lactams, beta lactam combination agents, and miscellaneous antibiotics. *J Emerg Med* 1996; **14**: 483–496.

17. Grossman RF. The role of fluoroquinolones in respiratory tract infections. *J Antimicrob Chemother* 1997; **40**(suppl A): 59–62.

18. Bakken JS. The fluoroquinolones: how long will their utility last? *Scand J Infect Dis* 2004; **36**: 85–92.

19. Lode H, Allewelt M. Role of newer fluoroquinolones in lower respiratory tract infections. *J Antimicrob Chemother* 2002; **50**: 151–154.

20. Fish DN. Levofloxacin: update and perspectives on one of the original 'respiratory quinolones'. *Expert Rev Anti Infect Ther* 2003; **1**: 371–387.

21. Ben David D, Rubinstein E. Appropriate use of antibiotics for respiratory infections: review of recent statements and position papers. *Curr Opin Infect Dis* 2002; **15**: 151–156.

22. Lacombe K, Cariou S, Tilleul P, Offenstadt G, Meynard JL. Optimizing fluoroquinolone utilization in a public hospital: a prospective study of educational intervention. *Eur J Clin Microbiol Infect Dis* 2005; **24**: 6–11.

23. Aubert G, Carricajo A, Vautrin AC *et al.* Impact of restricting fluoroquinolone prescription on bacterial resistance in an intensive care unit. *J Hosp Infect* 2005; **59**: 83–89.

24. Cars O, Molstad S, Melander A. Variation in antibiotic use in the European Union. *Lancet* 2001; **357**: 1851–1853.

25. Lesher GY, Foelich EJ, Gruett MD, Baily JH, Brundage PR. 1,8-Naphtyridine derivatives. A new class of chemotherapeutic agents. *J Med Pharm Chem* 1962; **91**: 1063–1065.

26. Bhanot SK, Singh M, Chatterjee NR. The chemical and biological aspects of fluoroquinolones: reality and dreams. *Curr Pharm Des* 2001; **7**: 311–335.

27. Ball P. Quinolone generations: natural history or natural selection? *J Antimicrob Chemother* 2000; **46**(suppl T1): 17–24.

28. Shen LL, Pernet AG. Mechanism of inhibition of DNA gyrase by analogues of nalidixic acid: the target of the drugs is DNA. *Proc Natl Acad Sci USA* 1985; **82**: 307–311.

29. Palu G, Valisena S, Ciarrocchi G, Gatto B, Palumbo M. Quinolone binding to DNA is mediated by magnesium ions. *Proc Natl Acad Sci USA* 1992; **89**: 9671–9675.

30. Khodursky AB, Zechiedrich EL, Cozzarelli NR. Topoisomerase IV is a target of quinolones in *Escherichia coli*. *Proc Natl Acad Sci USA* 1995; **92**: 11801–11805.

31. Morais Cabral JH, Jackson AP, Smith CV, Shikotra N, Maxwell A, Liddington RC. Crystal structure of the breakage-reunion domain of DNA gyrase. *Nature* 1997; **388**: 903–906.

32. Drlica K. Control of bacterial DNA supercoiling. *Mol Microbiol* 1992; **6**: 425–433.

33. Hooper DC. Fluoroquinolone resistance among Gram-positive cocci. *Lancet Infect Dis* 2002; **2**: 530–538.

34. Wigley DB. Structure and mechanism of DNA topoisomerases. *Ann Rev Biophys Biomol Struct* 1995; **24**: 185–208.

35. Drlica K, Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. *Microbiol Mol Biol Rev* 1997; **61**: 377–392.

36. Alovero FL, Pan XS, Morris JE, Manzo RH, Fisher LM. Engineering the specificity of antibacterial fluoroquino-

lones: benzenesulfonamide modifications at C-7 of ciprofloxacin change its primary target in *Streptococcus pneumoniae* from topoisomerase IV to gyrase. *Antimicrob Agents Chemother* 2000; **44**: 320–325.

37. Bryskier A, Chantot JF. Classification and structure–activity relationships of fluoroquinolones. *Drugs* 1995; **49**(suppl 2): 16–28.

38. Peterson LR. Quinolone molecular structure–activity relationships: what we have learned about improving antimicrobial activity. *Clin Infect Dis* 2001; **33**(suppl 3): S180–S186.

39. Pan XS, Fisher LM. DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in *Streptococcus pneumoniae*. *Antimicrob Agents Chemother* 1998; **42**: 2810–2816.

40. Fukuda H, Kishii R, Takei M, Hosaka M. Contributions of the 8-methoxy group of gatifloxacin to resistance selectivity, target preference, and antibacterial activity against *Streptococcus pneumoniae*. *Antimicrob Agents Chemother* 2001; **45**: 1649–1653.

41. Sanders CC. Mechanisms responsible for cross-resistance and dichotomous resistance among the quinolones. *Clin Infect Dis* 2001; **32**(suppl 1): S1–S8.

42. Janoir C, Podglajen I, Kitzis MD, Poyart C, Gutmann L. In vitro exchange of fluoroquinolone resistance determinants between *Streptococcus pneumoniae* and viridans streptococci and genomic organization of the *parE–parC* region in *S. mitis*. *J Infect Dis* 1999; **180**: 555–558.

43. Ferrandiz MJ, Fenoll A, Linares J, De La Campa AG. Horizontal transfer of *parC* and *gyrA* in fluoroquinolone-resistant clinical isolates of *Streptococcus pneumoniae*. *Antimicrob Agents Chemother* 2000; **44**: 840–847.

44. Yoshida H, Bogaki M, Nakamura M, Nakamura S. Quinolone resistance-determining region in the DNA gyrase *gyrA* gene of *Escherichia coli*. *Antimicrob Agents Chemother* 1990; **34**: 1271–1272.

45. Willmott CJ, Maxwell A. A single point mutation in the DNA gyrase A protein greatly reduces binding of fluoroquinolones to the gyrase–DNA complex. *Antimicrob Agents Chemother* 1993; **37**: 126–127.

46. Hooper DC. Mechanisms of fluoroquinolone resistance. *Drug Resist Update* 1999; **2**: 38–55.

47. Pan XS, Fisher LM. Targeting of DNA gyrase in *Streptococcus pneumoniae* by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones. *Antimicrob Agents Chemother* 1997; **41**: 471–474.

48. Fukuda H, Hiramatsu K. Primary targets of fluoroquinolones in *Streptococcus pneumoniae*. *Antimicrob Agents Chemother* 1999; **43**: 410–412.

49. Oizumi N, Kawabata S, Hirao M *et al.* Relationship between mutations in the DNA gyrase and topoisomerase IV genes and nadifloxacin resistance in clinically isolated quinolone-resistant *Staphylococcus aureus*. *J Infect Chemother* 2001; **7**: 191–194.

50. Rupp J, Gebert A, Solbach W, Maass M. Serine-to-asparagine substitution in the *gyrA* gene leads to quinolone resistance in moxifloxacin-exposed *Chlamydia pneumoniae*. *Antimicrob Agents Chemother* 2005; **49**: 406–407.

51. Gillespie SH, Voelker LL, Dickens A. Evolutionary barriers to quinolone resistance in *Streptococcus pneumoniae*. *Microb Drug Resist* 2002; **8**: 79–84.

52. Blanche F, Cameron B, Bernard FX *et al.* Differential behaviors of *Staphylococcus aureus* and *Escherichia coli* type II DNA topoisomerases. *Antimicrob Agents Chemother* 1996; **40**: 2714–2720.

53. Nishino Y, Deguchi T, Yasuda M *et al.* Mutations in the *gyrA* and *parC* genes associated with fluoroquinolone resistance in clinical isolates of *Citrobacter freundii*. *FEMS Microbiol Lett* 1997; **154**: 409–414.

54. Georgiou M, Munoz R, Roman F *et al.* Ciprofloxacin-resistant *Haemophilus influenzae* strains possess mutations in analogous positions of GyrA and ParC. *Antimicrob Agents Chemother* 1996; **40**: 1741–1744.

55. Deplano A, Zekhnini A, Allali N, Couturier M, Struelens MJ. Association of mutations in *grlA* and *gyrA* topoisomerase genes with resistance to ciprofloxacin in epidemic and sporadic isolates of methicillin-resistant *Staphylococcus aureus*. *Antimicrob Agents Chemother* 1997; **41**: 2023–2025.

56. Gootz TD, Zaniewski RP, Haskell SL, Kaczmarek FS, Maurice AE. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and *gyrA* and *grlA* mutants of *Staphylococcus aureus*. *Antimicrob Agents Chemother* 1999; **43**: 1845–1855.

57. Varon E, Janoir C, Kitzis MD, Gutmann L. ParC and GyrA may be interchangeable initial targets of some fluoroquinolones in *Streptococcus pneumoniae*. *Antimicrob Agents Chemother* 1999; **43**: 302–306.

58. Tankovic J, Bachoual R, Ouabdesselam S, Boudjadja A, Soussy CJ. In-vitro activity of moxifloxacin against fluoroquinolone-resistant strains of aerobic gram-negative bacilli and *Enterococcus faecalis*. *J Antimicrob Chemother* 1999; **43**(suppl B): 19–23.

59. Boswell FJ, Andrews JM, Jevons G, Wise R. Comparison of the in vitro activities of several new fluoroquinolones against respiratory pathogens and their abilities to select fluoroquinolone resistance. *J Antimicrob Chemother* 2002; **50**: 495–502.

60. Dong Y, Xu C, Zhao X, Domagala J, Drlica K. Fluoroquinolone action against mycobacteria: effects of C-8 substituents on growth, survival, and resistance. *Antimicrob Agents Chemother* 1998; **42**: 2978–2984.

61. Dalhoff A. Comparative in vitro and in vivo activity of the C-8 methoxy quinolone moxifloxacin and the C-8 chlorine quinolone BAY y 3118. *Clin Infect Dis* 2001; **32**(suppl 1): S16–S22.

62. Zhao X, Xu C, Domagala J, Drlica K. DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance. *Proc Natl Acad Sci USA* 1997; **94**: 13991–13996.

63. Hooper DC, Wolfson JS, Souza KS, Tung C, McHugh GL, Swartz MN. Genetic and biochemical characterization of norfloxacin resistance in *Escherichia coli*. *Antimicrob Agents Chemother* 1986; **29**: 639–644.

64. Legakis NJ, Tzouvelekis LS, Makris A, Kotsifaki H. Outer membrane alterations in multiresistant mutants of *Pseudomonas aeruginosa* selected by ciprofloxacin. *Antimicrob Agents Chemother* 1989; **33**: 124–127.

65. Nikaido H. Outer membrane barrier as a mechanism of antimicrobial resistance. *Antimicrob Agents Chemother* 1989; **33**: 1831–1836.

66. Van Bambeke F, Glupczynski Y, Plesiat P, Pechere JC, Tulkens PM. Antibiotic efflux pumps in prokaryotic cells: occurrence, impact on resistance and strategies for the future of antimicrobial therapy. *J Antimicrob Chemother* 2003; **51**: 1055–1065.

67. Saier MH, Paulsen IT, Sliwinski MK, Pao SS, Skurray RA, Nikaido H. Evolutionary origins of multidrug and drug-specific efflux pumps in bacteria. *FASEB J* 1998; **12**: 265–274.

68. Hsieh PC, Siegel SA, Rogers B, Davis D, Lewis K. Bacteria lacking a multidrug pump: a sensitive tool for drug discovery. *Proc Natl Acad Sci USA* 1998; **95**: 6602–6606.

69. Alonso A, Martinez JL. Multiple antibiotic resistance in *Stenotrophomonas maltophilia*. *Antimicrob Agents Chemother* 1997; **41**: 1140–1142.

70. Ghosh AS, Ahamed J, Chauhan KK, Kundu M. Involvement of an efflux system in high-level fluoroquinolone resistance of *Shigella dysenteriae*. *Biochem Biophys Res Commun* 1998; **242**: 54–56.

71. Zeller V, Janoir C, Kitzis MD, Gutmann L, Moreau NJ. Active efflux as a mechanism of resistance to ciprofloxacin in *Streptococcus pneumoniae*. *Antimicrob Agents Chemother* 1997; **41**: 1973–1978.

72. Kaatz GW, Seo SM. Mechanisms of fluoroquinolone resistance in genetically related strains of *Staphylococcus aureus*. *Antimicrob Agents Chemother* 1997; **41**: 2733–2737.

73. Lomovskaya O, Lee A, Hoshino K *et al.* Use of a genetic approach to evaluate the consequences of inhibition of efflux pumps in *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 1999; **43**: 1340–1346.

74. Beyer R, Pestova E, Millichap JJ, Stosor V, Noskin GA, Peterson LR. A convenient assay for estimating the possible involvement of efflux of fluoroquinolones by *Streptococcus pneumoniae* and *Staphylococcus aureus*: evidence for diminished moxifloxacin, sparfloxacin, and trovafloxacin efflux. *Antimicrob Agents Chemother* 2000; **44**: 798–801.

75. Boswell FJ, Andrews JM, Wise R. Comparison of the in vitro activities of BMS-284756 and four fluoroquinolones against *Streptococcus pneumoniae*. *J Antimicrob Chemother* 2001; **48**: 446–447.

76. Zhanel GG, Walkty A, Nichol K, Smith H, Noreddin A, Hoban DJ. Molecular characterization of fluoroquinolone resistant *Streptococcus pneumoniae* clinical isolates obtained from across Canada. *Diagn Microbiol Infect Dis* 2003; **45**: 63–67.

77. Grohs P, Houssaye S, Aubert A, Gutmann L, Varon E. In vitro activities of garenoxacin (BMS-284756) against *Streptococcus pneumoniae*, viridans group streptococci, and *Enterococcus faecalis* compared to those of six other quinolones. *Antimicrob Agents Chemother* 2003; **47**: 3542–3547.

78. Brenwald NP, Gill MJ, Wise R. Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of *Streptococcus pneumoniae*. *Antimicrob Agents Chemother* 1998; **42**: 2032–2035.

79. Gill MJ, Brenwald NP, Wise R. Identification of an efflux pump gene, *pmrA*, associated with fluoroquinolone resistance in *Streptococcus pneumoniae*. *Antimicrob Agents Chemother* 1999; **43**: 187–189.

80. Munoz-Bellido JL, Alonzo MM, Martinez Andres JA *et al.* Efflux pump-mediated quinolone resistance in *Staphylococcus aureus* strains wild type for *gyrA*, *gyrB*, *grlA*, and *norA*. *Antimicrob Agents Chemother* 1999; **43**: 354–356.

81. Aeschlimann JR, Dresser LD, Kaatz GW, Rybak MJ. Effects of NorA inhibitors on in vitro antibacterial activities and postantibiotic effects of levofloxacin, ciprofloxacin, and norfloxacin in genetically related strains of *Staphylococcus aureus*. *Antimicrob Agents Chemother* 1999; **43**: 335–340.

82. Miyamae S, Nikaido H, Tanaka Y, Yoshimura F. Active efflux of norfloxacin by *Bacteroides fragilis*. *Antimicrob Agents Chemother* 1998; **42**: 2119–2121.

83. Mine T, Morita Y, Kataoka A, Mizushima T, Tsuchiya T. Expression in *Escherichia coli* of a new multidrug efflux pump, MexXY, from *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 1999; **43**: 415–417.

84. Ziha-Zarifi I, Llanes C, Kohler T, Pechere JC, Plesiat P. In vivo emergence of multidrug-resistant mutants of *Pseudomonas aeruginosa* overexpressing the active efflux system MexA–MexB–OprM. *Antimicrob Agents Chemother* 1999; **43**: 287–291.

85. Martinez-Martinez L, Pascual A, Jacoby GA. Quinolone resistance from a transferable plasmid. *Lancet* 1998; **351**: 797–799.

86. Wang M, Tran JH, Jacoby GA, Zhang Y, Wang F, Hooper DC. Plasmid-mediated quinolone resistance in clinical isolates of *Escherichia coli* from Shanghai, China. *Antimicrob Agents Chemother* 2003; **47**: 2242–2248.

87. Tran JH, Jacoby GA. Mechanism of plasmid-mediated quinolone resistance. *Proc Natl Acad Sci USA* 2002; **99**: 5638–5642.

88. Tran JH, Jacoby GA, Hooper DC. Interaction of the plasmid-encoded quinolone resistance protein Qnr with *Escherichia coli* DNA gyrase. *Antimicrob Agents Chemother* 2005; **49**: 118–125.

89. Rodriguez-Martinez JM, Pascual A, Garcia I, Martinez-Martinez L. Detection of the plasmid-mediated quinolone resistance determinant *qnr* among clinical isolates of *Klebsiella pneumoniae* producing AmpC-type beta-lactamase. *J Antimicrob Chemother* 2003; **52**: 703–706.

90. Mammeri H, Van De LM, Poirel L, Martinez-Martinez L, Nordmann P. Emergence of plasmid-mediated quinolone resistance in *Escherichia coli* in Europe. *Antimicrob Agents Chemother* 2005; **49**: 71–76.

91. Cunha BA. Intravenous to oral antibiotic switch therapy. *Drugs Today (Barc)* 2001; **37**: 311–319.

92. Phillips I, King A. Comparative activity of the 4-quinolones. *Rev Infect Dis* 1988; **10**(suppl 1): S70–S76.

93. Roosendaal R, Bakker-Woudenberg IA, van den Berghe-van Raffe M, Vink-van den Berg JC, Michel MF. Comparative activities of ciprofloxacin and ceftazidime against *Klebsiella pneumoniae* in vitro and in experimental pneumonia in leukopenic rats. *Antimicrob Agents Chemother* 1987; **31**: 1809–1815.

94. Chin NX, Neu HC. Post-antibiotic suppressive effect of ciprofloxacin against gram-positive and gram-negative bacteria. *Am J Med* 1987; **82**: 58–62.

95. Drusano GL, Johnson DE, Rosen M, Standiford HC. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of *Pseudomonas* sepsis. *Antimicrob Agents Chemother* 1993; **37**: 483–490.

96. Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs. *Int J Antimicrob Agents* 2002; **19**: 355–358.

97. Peloquin CA, Cumbo TJ, Nix DE, Sands MF, Schentag JJ. Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of

plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication. *Arch Intern Med* 1989; **149**: 2269–2273.

98. Lee BL, Padula AM, Kimbrough RC *et al.* Infectious complications with respiratory pathogens despite ciprofloxacin therapy. *N Engl J Med* 1991; **325**: 520–521.

99. Nix DE, Sands MF, Peloquin CA *et al.* Dual individualization of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. *Am J Med* 1987; **82**: 352–356.

100. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. *Antimicrob Agents Chemother* 1993; **37**: 1073–1081.

101. Preston SL, Drusano GL, Berman AL *et al.* Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. *JAMA* 1998; **279**: 125–129.

102. Ambrose PG, Bhavnani SM, Owens RC. Clinical pharmacodynamics of quinolones. *Infect Dis Clin North Amer* 2003; **17**: 529–543.

103. Jones RN, Rubino CM, Bhavnani SM, Ambrose PG. Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against *Streptococcus pneumoniae:* report from the Antimicrobial Resistance Rate Epidemiology Study Team. *Antimicrob Agents Chemother* 2003; **47**: 292–296.

104. Owens RC, Bhavnani SM, Ambrose PG. Assessment of pharmacokinetic–pharmacodynamic target attainment of gemifloxacin against *Streptococcus pneumoniae. Diagn Microbiol Infect Dis* 2005; **51**: 45–49.

105. Jacobs MR. Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters. *Clin Microbiol Infect* 2001; **7**: 589–596.

106. Schentag JJ, Meagher AK, Forrest A. Fluoroquinolone AUIC break points and the link to bacterial killing rates. Part 1: In vitro and animal models. *Ann Pharmacother* 2003; **37**: 1287–1298.

107. Klepser ME, Ernst EJ, Petzold CR, Rhomberg P, Doern GV. Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against *Streptococcus pneumoniae* in a dynamic in vitro model. *Antimicrob Agents Chemother* 2001; **45**: 673–678.

108. Andes D, Craig WA. Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models. *Antimicrob Agents Chemother* 2002; **46**: 1665–1670.

109. Schentag JJ, Meagher AK, Forrest A. Fluoroquinolone AUIC break points and the link to bacterial killing rates. Part 2: human trials. *Ann Pharmacother* 2003; **37**: 1478–1488.

110. Drusano GL. Pharmacokinetics of the quinolone antimicrobial agents. In: Wolfson JS, Hooper DC, eds. *Quinolone antimicrobial agents*. Washington, DC: American Society for Microbiology, 1989; 71–106.

111. Kays MB, Graff MA. Broth microdilution and E-test for determining fluoroquinolone activity against *Streptococcus pneumoniae. Ann Pharmacother* 2002; **36**: 416–422.

112. Nicolau DP, Mattoes HM, Banevicius M, Xuan D, Nightingale CH. Pharmacodynamics of a novel des-F (6)-quinolone, BMS-284756, against *Streptococcus pneumoniae* in the thigh infection model. *Antimicrob Agents Chemother* 2003; **47**: 1630–1635.

113. Zeitlinger MA, Sauermann R, Traunmuller F, Georgopoulos A, Muller M, Joukhadar C. Impact of plasma protein binding on antimicrobial activity using time-killing curves. *J Antimicrob Chemother* 2004; **54**: 876–880.

114. Thomas JK, Forrest A, Bhavnani SM *et al.* Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. *Antimicrob Agents Chemother* 1998; **42**: 521–527.

115. Firsov AA, Zinner SH, Vostrov SN, Portnoy YA, Lubenko IY. AUC/MIC relationships to different endpoints of the antimicrobial effect: multiple-dose in vitro simulations with moxifloxacin and levofloxacin. *J Antimicrob Chemother* 2002; **50**: 533–539.

116. Zinner SH, Lubenko IY, Gilbert D *et al.* Emergence of resistant *Streptococcus pneumoniae* in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing. *J Antimicrob Chemother* 2003; **52**: 616–622.

117. MacGowan AP, Rogers CA, Holt HA, Bowker KE. Activities of moxifloxacin against, and emergence of resistance in, *Streptococcus pneumoniae* and *Pseudomonas aeruginosa* in an in vitro pharmacokinetic model. *Antimicrob Agents Chemother* 2003; **47**: 1088–1095.

118. Gumbo T, Louie A, Deziel MR, Parsons LM, Salfinger M, Drusano GL. Selection of a moxifloxacin dose that suppresses drug resistance in *Mycobacterium tuberculosis*, by use of an in vitro pharmacodynamic infection model and mathematical modeling. *J Infect Dis* 2004; **190**: 1642–1651.

119. Jumbe N, Louie A, Leary R *et al.* Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. *J Clin Invest* 2003; **112**: 275–285.

120. Drlica K. Refining the fluoroquinolones. *ASM News* 1999; **65**: 410–415.

121. Blondeau JM, Zhao X, Hansen G, Drlica K. Mutant prevention concentrations of fluoroquinolones for clinical isolates of *Streptococcus pneumoniae. Antimicrob Agents Chemother* 2001; **45**: 433–438.

122. Hansen GT, Metzler K, Drlica K, Blondeau JM. Mutant prevention concentration of gemifloxacin for clinical isolates of *Streptococcus pneumoniae. Antimicrob Agents Chemother* 2003; **47**: 440–441.

123. Zhao X, Eisner W, Perl-Rosenthal N, Kreiswirth B, Drlica K. Mutant prevention concentration of garenoxacin (BMS-284756) for ciprofloxacin-susceptible or -resistant *Staphylococcus aureus. Antimicrob Agents Chemother* 2003; **47**: 1023–1027.

124. Firsov AA, Vostrov SN, Lubenko IY, Drlica K, Portnoy YA, Zinner SH. In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against *Staphylococcus aureus. Antimicrob Agents Chemother* 2003; **47**: 1604–1613.

125. Lu T, Zhao X, Li X, Hansen G, Blondeau J, Drlica K. Effect of chloramphenicol, erythromycin, moxifloxacin, penicillin and tetracycline concentration on the recovery of resistant mutants of *Mycobacterium smegmatis* and *Staphylococcus aureus. J Antimicrob Chemother* 2003; **52**: 61–64.

126. Randall LP, Cooles SW, Piddock LJ, Woodward MJ. Mutant prevention concentrations of ciprofloxacin and enrofloxacin for *Salmonella enterica. J Antimicrob Chemother* 2004; **54**: 688–691.

127. Linde HJ, Lehn N. Mutant prevention concentration of nalidixic acid, ciprofloxacin, clinafloxacin, levofloxacin, norfloxacin, ofloxacin, sparfloxacin or trovafloxacin for *Escherichia coli* under different growth conditions. *J Antimicrob Chemother* 2004; **53**: 252–257.

128. Li X, Mariano N, Rahal JJ, Urban CM, Drlica K. Quinolone-resistant *Haemophilus influenzae*: determination of mutant selection window for ciprofloxacin, garenoxacin, levofloxacin, and moxifloxacin. *Antimicrob Agents Chemother* 2004; **48**: 4460–4462.

129. Zhao X, Drlica K. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. *Clin Infect Dis* 2001; **33**(suppl 3): S147–S156.

130. Epstein BJ, Gums JG, Drlica K. The changing face of antibiotic prescribing: the mutant selection window. *Ann Pharmacother* 2004; **38**: 1675–1682.

131. Allen GP, Kaatz GW, Rybak MJ. Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against *Streptococcus pneumoniae* in an in vitro pharmacodynamic model. *Antimicrob Agents Chemother* 2003; **47**: 2606–2614.

132. Smith HJ, Walters M, Hisanaga T, Zhanel GG, Hoban DJ. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing *Streptococcus pneumoniae* isolates. *Antimicrob Agents Chemother* 2004; **48**: 3954–3958.

133. Croisier D, Etienne M, Bergoin E *et al.* Mutant selection window in levofloxacin and moxifloxacin treatments of experimental pneumococcal pneumonia in a rabbit model of human therapy. *Antimicrob Agents Chemother* 2004; **48**: 1699–1707.

134. Blondeau JM, Hansen G, Metzler K, Hedlin P. The role of PK/PD parameters to avoid selection and increase of resistance: mutant prevention concentration. *J Chemother* 2004; **16**(suppl 3): 1–19.

135. Nightingale CH. Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic–pharmacodynamic characteristics. *Pharmacotherapy* 2000; **20**: 245–256.

136. Obritsch MD, Fish DN, MacLaren R, Jung R. National surveillance of antimicrobial resistance in *Pseudomonas aeruginosa* isolates obtained from intensive care unit patients from 1993 to 2002. *Antimicrob Agents Chemother* 1993; **48**: 4606–4610.

137. Astal Z. Susceptibility patterns in *Pseudomonas aeruginosa* causing nosocomial infections. *J Chemother* 2004; **16**: 264–268.

138. Jang CH, Park SY. Emergence of ciprofloxacin-resistant pseudomonas in chronic suppurative otitis media. *Clin Otolaryngol* 2004; **29**: 321–323.

139. Lau SM, Peng MY, Chang FY. Resistance rates to commonly used antimicrobials among pathogens of both bacteremic and non-bacteremic community-acquired urinary tract infection. *J Microbiol Immunol Infect* 2004; **37**: 185–191.

140. Jung R, Fish DN, Obritsch MD, MacLaren R. Surveillance of multi-drug resistant *Pseudomonas aeruginosa* in an urban tertiary-care teaching hospital. *J Hosp Infect* 2004; **57**: 105–111.

141. Cermak P, Kolar M, Latal T. Frequency of Gram-negative bacterial pathogens in bloodstream infections and their resistance to antibiotics in the Czech Republic. *Int J Antimicrob Agents* 2004; **23**: 401–404.

142. Unal S, Masterton R, Goossens H. Bacteraemia in Europe—antimicrobial susceptibility data from the MYSTIC surveillance programme. *Int J Antimicrob Agents* 2004; **23**: 155–163.

143. De Vecchi E, Drago L, Nicola L *et al.* Resistance of *Pseudomonas aeruginosa* to ciprofloxacin and levofloxacin: 1998–2002. *Infez Med* 2003; **11**: 196–200.

144. Kern WV, Steib-Bauert M, de With K *et al.* Fluoroquinolone consumption and resistance in haematology–oncology patients: ecological analysis in two university hospitals 1999–2002. *J Antimicrob Chemother* 2005; **55**: 57–60.

145. Polk RE, Johnson CK, McClish D, Wenzel RP, Edmond MB. Predicting hospital rates of fluoroquinolone-resistant *Pseudomonas aeruginosa* from fluoroquinolone use in US hospitals and their surrounding communities. *Clin Infect Dis* 2004; **39**: 497–503.

146. Meyer E, Jonas D, Schwab F, Gastmeier P, Ruden H, Daschner FD. SARI: surveillance of antibiotic use and bacterial resistance in German intensive care units. Correlation between antibiotic use and the emergence of resistance. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz* 2004; **47**: 345–351.

147. Mohr JF, Jones A, Ostrosky-Zeichner L, Wanger A, Tillotson G. Associations between antibiotic use and changes in susceptibility patterns of *Pseudomonas aeruginosa* in a private, university-affiliated teaching hospital: an 8-year-experience: 1995–2002. *Int J Antimicrob Agents* 2004; **24**: 346–351.

148. Karlowsky JA, Thornsberry C, Jones ME, Sahm DF. Susceptibility of antimicrobial-resistant urinary *Escherichia coli* isolates to fluoroquinolones and nitrofurantoin. *Clin Infect Dis* 2003; **36**: 183–187.

149. Abelson SK, Osterlund A, Kahlmeter G. Antimicrobial resistance in *Escherichia coli* in urine samples from children and adults: a 12 year analysis. *Acta Paediatr* 2004; **93**: 487–491.

150. Kahlmeter G, Menday P, Cars O. Non-hospital antimicrobial usage and resistance in community-acquired *Escherichia coli* urinary tract infection. *J Antimicrob Chemother* 2003; **52**: 1005–1010.

151. Kahlmeter G. Prevalence and antimicrobial susceptibility of pathogens in uncomplicated cystitis in Europe. The ECO.SENS study. *Int J Antimicrob Agents* 2003; **22**(suppl 2): 49–52.

152. Canton R, Morosini M, Enright MC, Morrissey I. Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant *Streptococcus pneumoniae*: data from the global PROTEKT surveillance programme. *J Antimicrob Chemother* 2003; **52**: 944–952.

153. Karlowsky JA, Thornsberry C, Jones ME, Evangelista AT, Critchley IA, Sahm DF. Factors associated with relative rates of antimicrobial resistance among *Streptococcus pneumoniae* in the United States: results from the TRUST Surveillance Program (1998–2002). *Clin Infect Dis* 2003; **36**: 963–970.

154. Jacobs MR, Felmingham D, Appelbaum PC, Gruneberg RN. The Alexander Project 1998–2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. *J Antimicrob Chemother* 2003; **52**: 229–246.

155. Chen DK, McGeer A, de Azavedo JC, Low DE. Decreased susceptibility of *Streptococcus pneumoniae* to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. *N Engl J Med* 1999; **341**: 233–239.

156. Ho PL, Que TL, Tsang DN, Ng TK, Chow KH, Seto WH. Emergence of fluoroquinolone resistance among multiply resistant strains of *Streptococcus pneumoniae* in Hong Kong. *Antimicrob Agents Chemother* 1999; **43**: 1310–1313.

157. Ho PL, Tse WS, Tsang KW *et al.* Risk factors for acquisition of levofloxacin-resistant *Streptococcus pneumoniae*: a case-control study. *Clin Infect Dis* 2001; **32**: 701–707.

158. Bhavnani SM, Hammel JP, Jones RN, Ambrose PG. Relationship between increased levofloxacin use and decreased susceptibility of *Streptococcus pneumoniae* in the United States. *Diagn Microbiol Infect Dis* 2005; **51**: 31–37.

159. Davidson R, Cavalcanti R, Brunton JL *et al.* Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. *N Engl J Med* 2002; **346**: 747–750.

160. Oteo J, Lazaro E, de Abajo FJ, Baquero F, Campos J. Trends in antimicrobial resistance in 1,968 invasive *Streptococcus pneumoniae* strains isolated in Spanish hospitals (2001 to 2003): decreasing penicillin resistance in children's isolates. *J Clin Microbiol* 2004; **42**: 5571–5577.

161. Pletz MW, McGee L, Jorgensen J *et al.* Levofloxacin-resistant invasive *Streptococcus pneumoniae* in the United States: evidence for clonal spread and the impact of conjugate pneumococcal vaccine. *Antimicrob Agents Chemother* 2004; **48**: 3491–3497.

162. Yokota S, Sato K, Yoshida S, Fujii N. Molecular epidemiology of fluoroquinolone-resistant *Streptococcus pneumoniae* in Japan. *Kansenshogaku Zasshi* 2004; **78**: 428–434.

163. Klugman KP. The role of clonality in the global spread of fluoroquinolone-resistant bacteria. *Clin Infect Dis* 2003; **36**: 783–785.

164. Blumberg HM, Rimland D, Carroll DJ, Terry P, Wachsmuth IK. Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant *Staphylococcus aureus*. *J Infect Dis* 1991; **163**: 1279–1285.

165. Andersson DI. Persistence of antibiotic resistant bacteria. *Curr Opin Microbiol* 2003; **6**: 452–456.

166. Luo N, Pereira S, Sahin O *et al.* Enhanced in vivo fitness of fluoroquinolone-resistant *Campylobacter jejuni* in the absence of antibiotic selection pressure. *Proc Natl Acad Sci USA* 2005; **102**: 541–546.

167. Bastida T, Perez-Vazquez M, Campos J *et al.* Levofloxacin treatment failure in *Haemophilus influenzae* pneumonia. *Emerg Infect Dis* 2003; **9**: 1475–1478.

168. Low DE. Quinolone resistance among pneumococci: therapeutic and diagnostic implications. *Clin Infect Dis* 2004; **38**(suppl 4): S357–S362.

169. Capitano B, Mattoes HM, Shore E *et al.* Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults. *Chest* 2004; **125**: 965–973.

170. O'Donnell JA, Gelone SP. The newer fluoroquinolones. *Infect Dis Clin North Am* 2004; **18**: 691–716.

171. Wagenlehner FM, Naber KG. Fluoroquinolone antimicrobial agents in the treatment of prostatitis and recurrent urinary tract infections in men. *Curr Infect Dis Rep* 2005; **7**: 9–16.

172. Cottagnoud P, Tauber MG. Fluoroquinolones in the treatment of meningitis. *Curr Infect Dis Rep* 2003; **5**: 329–336.

173. Pascual A, Garcia I, Ballesta S, Perea EJ. Uptake and intracellular activity of moxifloxacin in human neutrophils and tissue-cultured epithelial cells. *Antimicrob Agents Chemother* 1999; **43**: 12–15.

174. Carlier MB, Scorneaux B, Zenebergh A, Desnottes JF, Tulkens PM. Cellular uptake, localization and activity of fluoroquinolones in uninfected and infected macrophages. *J Antimicrob Chemother* 1990; **26**(suppl B): 27–39.

175. Walters JD, Zhang F, Nakkula RJ. Mechanisms of fluoroquinolone transport by human neutrophils. *Antimicrob Agents Chemother* 1999; **43**: 2710–2715.

176. Bounds SJ, Nakkula R, Walters JD. Fluoroquinolone transport by human monocytes: characterization and comparison to other cells of myeloid lineage. *Antimicrob Agents Chemother* 2000; **44**: 2609–2614.

177. Seral C, Carryn S, Tulkens PM, Van Bambeke F. Influence of P-glycoprotein and MRP efflux pump inhibitors on the intracellular activity of azithromycin and ciprofloxacin in macrophages infected by *Listeria monocytogenes* or *Staphylococcus aureus*. *J Antimicrob Chemother* 2003; **51**: 1167–1173.

178. Hall IH, Schwab UE, Ward ES, Ives T. Disposition and intracellular levels of moxifloxacin in human THP-1 monocytes in unstimulated and stimulated conditions. *Int J Antimicrob Agents* 2003; **22**: 579–587.

179. Carryn S, Chanteux H, Seral C, Mingeot-Leclercq MP, Van Bambeke F, Tulkens PM. Intracellular pharmacodynamics of antibiotics. *Infect Dis Clin North Amer* 2003; **17**: 615–634.

180. Carryn S, Van Bambeke F, Mingeot-Leclercq MP, Tulkens PM. Comparative intracellular (THP-1 macrophage) and extracellular activities of beta-lactams, azithromycin, gentamicin, and fluoroquinolones against *Listeria monocytogenes* at clinically relevant concentrations. *Antimicrob Agents Chemother* 2002; **46**: 2095–2103.

181. Chang HR, Vladoianu IR, Pechere JC. Effects of ampicillin, ceftriaxone, chloramphenicol, pefloxacin and trimethoprim–sulphamethoxazole on *Salmonella typhi* within human monocyte-derived macrophages. *J Antimicrob Chemother* 1990; **26**: 689–694.

182. Jonas D, Engels I, Friedhoff C, Spitzmuller B, Daschner FD, Frank U. Efficacy of moxifloxacin, trovafloxacin, clinafloxacin and levofloxacin against intracellular *Legionella pneumophila*. *J Antimicrob Chemother* 2001; **47**: 147–152.

183. Borsum T, Dannevig L, Storvold G, Melby K. *Chlamydia trachomatis*: in vitro susceptibility of genital and ocular isolates to some quinolones, amoxicillin and azithromycin. *Chemotherapy* 1990; **36**: 407–415.

184. Fenelon LE, Mumtaz G, Ridgway GL. The in-vitro antibiotic susceptibility of *Chlamydia pneumoniae*. *J Antimicrob Chemother* 1990; **26**: 763–767.

185. Sato K, Tomioka H, Sano C *et al.* Comparative antimicrobial activities of gatifloxacin, sitafloxacin and levofloxacin against *Mycobacterium tuberculosis* replicating within Mono Mac 6 human macrophage and A-549 type II alveolar cell lines. *J Antimicrob Chemother* 2003; **52**: 199–203.

186. Seral C, Van Bambeke F, Tulkens PM. Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular *Staphylococcus aureus* in mouse J774 macrophages. *Antimicrob Agents Chemother* 2003; **47**: 2283–2292.

187. Ahren IL, Karlsson E, Forsgren A, Riesbeck K. Comparison of the antibacterial activities of ampicillin, ciprofloxacin, clarithromycin, telithromycin and quinu-pristin/dalfopristin against intracellular non-typeable *Haemophilus influenzae*. *J Antimicrob Chemother* 2002; **50**: 903–906.

188. Nichterlein T, Bornitz F, Kretschmar M, Hof H. Successful treatment of murine listeriosis and salmonellosis with levofloxacin. *J Chemother* 1998; **10**: 313–319.

189. Edelstein PH, Shinzato T, Edelstein MA. BMS-284756 (T-3811ME) a new fluoroquinolone: in vitro activity against *Legionella*, efficacy in a guinea pig model of *L. pneumophila* pneumonia and pharmacokinetics in guinea pigs. *J Antimicrob Chemother* 2001; **48**: 667–675.

190. Yoshimatsu T, Nuermberger E, Tyagi S, Chaisson R, Bishai W, Grosset J. Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuber-culosis. *Antimicrob Agents Chemother* 2002; **46**: 1875–1879.

191. Nakata K, Maeda H, Fujii A, Arakawa S, Umezu K, Kamidono S. In vitro and in vivo activities of sparfloxa-cin, other quinolones, and tetracyclines against *Chlamydia trachomatis*. *Antimicrob Agents Chemother* 1992; **36**: 188–190.

192. Miyashita N, Niki Y, Kishimoto T, Nakajima M, Matsu-shima T. In vitro and in vivo activities of AM-1155, a new fluoroquinolone, against *Chlamydia* spp. *Antimicrob Agents Chemother* 1997; **41**: 1331–1334.

193. Dunbar LM, Khashab MM, Kahn JB, Zadeikis N, Xiang JX, Tennenberg AM. Efficacy of 750-mg, 5-day levofl-oxacin in the treatment of community-acquired pneu-monia caused by atypical pathogens. *Curr Med Res Opin* 2004; **20**: 555–563.

194. Santos J, Aguilar L, Garcia-Mendez E *et al.* Clinical characteristics and response to newer quinolones in *Legionella pneumonia*: a report of 28 cases. *J Chemother* 2003; **15**: 461–465.

195. Yu VL, Greenberg RN, Zadeikis N *et al.* Levofloxacin efficacy in the treatment of community-acquired legio-nellosis. *Chest* 2004; **125**: 2135–2139.

196. Gosling RD, Uiso LO, Sam NE *et al.* The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. *Am J Respir Crit Care Med* 2003; **168**: 1342–1345.

197. Valerio G, Bracciale P, Manisco V, Quitadamo M, Legari G, Bellanova S. Long-term tolerance and effectiveness of moxifloxacin therapy for tuberculosis: preliminary results. *J Chemother* 2003; **15**: 66–70.

198. Yew WW, Chan CK, Leung CC *et al.* Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospec-tive study from Hong Kong. *Chest* 2003; **124**: 1476–1481.

199. Van Bambeke F, Balzi E, Tulkens PM. Antibiotic efflux pumps. *Biochem Pharmacol* 2000; **60**: 457–470.

200. Sasabe H, Kato Y, Suzuki T, Itose M, Miyamoto G, Sug-iyama Y. Differential involvement of multidrug resist-ance-associated protein 1 and p-glycoprotein in tissue distribution and excretion of grepafloxacin in mice. *J Pharmacol Exp Ther* 2004; **310**: 648–655.

201. Foote EF, Halstenson CE. Effects of probenecid and cimetidine on renal disposition of ofloxacin in rats. *Antimicrob Agents Chemother* 1998; **42**: 456–458.

202. Ito T, Yano I, Tanaka K, Inui KI. Transport of quinolone antibacterial drugs by human P-glycoprotein expressed

in a kidney epithelial cell line, LLC-PK1. *J Pharmacol Exp Ther* 1997; **282**: 955–960.

203. Sasabe H, Terasaki T, Tsuji A, Sugiyama Y. Carrier-mediated hepatic uptake of quinolone antibiotics in the rat. *J Pharmacol Exp Ther* 1997; **282**: 162–171.

204. Sasabe H, Tsuji A, Sugiyama Y. Carrier-mediated mech-anism for the biliary excretion of the quinolone antibiotic grepafloxacin and its glucuronide in rats. *J Pharmacol Exp Ther* 1998; **284**: 1033–1039.

205. De Sarro A, Cecchetti V, Fravolini V, Naccari F, Tabarrini O, De Sarro G. Effects of novel 6-desfluoroquinolones and classic quinolones on pentylenetetrazole-induced sei-zures in mice. *Antimicrob Agents Chemother* 1999; **43**: 1729–1736.

206. Ooie T, Terasaki T, Suzuki H, Sugiyama Y. Kinetic evi-dence for active efflux transport across the blood–brain barrier of quinolone antibiotics. *J Pharmacol Exp Ther* 1997; **283**: 293–304.

207. Recanatini M, Poluzzi E, Masetti M, Cavalli A, De Ponti F. QT prolongation through hERG K (+) channel blockade: current knowledge and strategies for the early prediction during drug development. *Med Res Rev* 2005; **25**: 133–166.

208. Blum MD, Graham DJ, McCloskey CA. Temafloxacin syndrome: review of 95 cases. *Clin Infect Dis* 1994; **18**: 946–950.

209. Chen HJ, Bloch KJ, Maclean JA. Acute eosinophilic hepa-titis from trovafloxacin. *N Engl J Med* 2000; **342**: 359–360.

210. Ball P, Stahlmann R, Kubin R, Choudhri S, Owens R. Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies. *Clin Ther* 2004; **26**: 940–950.

211. Temime L, Boelle PY, Courvalin P, Guillemot D. Bacterial resistance to penicillin G by decreased affinity of peni-cillin-binding proteins: a mathematical model. *Emerg Infect Dis* 2003; **9**: 411–417.

212. Lautenbach E, Strom BL, Nachamkin I *et al.* Longitudinal trends in fluoroquinolone resistance among Enterobacte-riaceae isolates from inpatients and outpatients, 1989–2000: differences in the emergence and epidemiology of resistance across organisms. *Clin Infect Dis* 2004; **38**: 655–662.

213. Chaniotaki S, Giakouppi P, Tzouvelekis LS *et al.* Quino-lone resistance among *Escherichia coli* strains from com-munity-acquired urinary tract infections in Greece. *Clin Microbiol Infect* 2004; **10**: 75–78.

214. Carbon C, Isturiz R. Narrow versus broad spectrum antibacterials: factors in the selection of pneumococcal resistance to beta-lactams. *Drugs* 2002; **62**: 1289–1294.

215. Carbon C, Cars O, Christiansen K. Moving from recom-mendation to implementation and audit: part 1. Current recommendations and programs: a critical commentary. *Clin Microbiol Infect* 2002; **8**(suppl 2): 92–106.

216. Christiansen K, Carbon C, Cars O. Moving from recom-mendation to implementation and audit: part 2. Review of interventions and audit. *Clin Microbiol Infect* 2002; **8**(suppl 2): 107–128.

217. Appelbaum PC, Gillespie SH, Burley CJ, Tillotson GS. Antimicrobial selection for community-acquired lower respiratory tract infections in the 21st century: a review of gemifloxacin. *Int J Antimicrob Agents* 2004; **23**: 533–546.

218. Halpern MT, Palmer CS, Zodet M, Kirsch J. Cost-effect-iveness of gemifloxacin: results from the GLOBE study. *Am J Health Syst Pharm* 2002; **59**: 1357–1365.

219. Madan AK. Use of ciprofloxacin in the treatment of hospitalized patients with intra-abdominal infections. *Clin Ther* 2004; **26**: 1564–1577.

220. Drummond MF, Becker DL, Hux M *et al.* An economic evaluation of sequential i.v./po moxifloxacin therapy compared to i.v./po co-amoxiclav with or without clarithromycin in the treatment of community-acquired pneumonia. *Chest* 2003; **124**: 526–535.

221. Fischer MA, Solomon DH, Teich JM, Avorn J. Conversion from intravenous to oral medications: assessment of a computerized intervention for hospitalized patients. *Arch Intern Med* 2003; **163**: 2585–2589.

222. Kuti JL, Le TN, Nightingale CH, Nicolau DP, Quintiliani R. Pharmacoeconomics of a pharmacist-managed program for automatically converting levofloxacin route from i.v. to oral. *Am J Health Syst Pharm* 2002; **59**: 2209–2215.

223. Pablos AI, Escobar I, Albinana S, Serrano O, Ferrari JM, de Tejada AH. Evaluation of an antibiotic intravenous to oral sequential therapy program. *Pharmacoepidemiol Drug Safety* 2005; **14**: 53–59.

224. Nickel JC. Management of urinary tract infections: historical perspective and current strategies: Part 2—Modern management. *J Urol* 2005; **173**: 27–32.

225. Louie TJ. Ciprofloxacin: an oral quinolone for the treatment of infections with gram-negative pathogens. Committee on Antimicrobial Agents. Canadian Infectious Disease Society. *Can Med Assoc J* 1994; **150**: 669–676.

226. File TM, Garau J, Blasi F *et al.* Guidelines for empiric antimicrobial prescribing in community-acquired pneumonia. *Chest* 2004; **125**: 1888–1901.

227. Martinez FJ. Monotherapy versus dual therapy for community-acquired pneumonia in hospitalized patients. *Clin Infect Dis* 2004; **38**(suppl 4): S328–S340.

228. Finch R, Schurmann D, Collins O *et al.* Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. *Antimicrob Agents Chemother* 2002; **46**: 1746–1754.

229. Desenclos JC, Guillemot D. Consequences of bacterial resistance to antimicrobial agents. *Emerg Infect Dis* 2004; **10**: 759–760.

230. Hecht DW. Prevalence of antibiotic resistance in anaerobic bacteria: worrisome developments. *Clin Infect Dis* 2004; **39**: 92–97.

231. Ackermann G, Tang-Feldman YJ, Schaumann R *et al.* Antecedent use of fluoroquinolones is associated with resistance to moxifloxacin in *Clostridium difficile*. *Clin Microbiol Infect* 2003; **9**: 526–530.

232. Ricci V, Peterson ML, Rotschafer JC, Wexler H, Piddock LJ. Role of topoisomerase mutations and efflux in fluoroquinolone resistance of *Bacteroides fragilis* clinical isolates and laboratory mutants. *Antimicrob Agents Chemother* 2004; **48**: 1344–1346.

233. Scheld WM. Maintaining fluoroquinolone class efficacy: review of influencing factors. *Emerg Infect Dis* 2003; **9**: 1–9.

234. Hooper DC. Minimizing potential resistance: the molecular view—a comment on Courvalin and Trieu-Cuot. *Clin Infect Dis* 2001; **33**(suppl 3): S157–S160.

235. Courvalin P, Trieu-Cuot P. Minimizing potential resistance: the molecular view. *Clin Infect Dis* 2001; **33**(suppl 3): S138–S146.

236. Kishii R, Takei M, Fukuda H, Hayashi K, Hosaka M. Contribution of the 8-methoxy group to the activity of gatifloxacin against type II topoisomerases of *Streptococcus pneumoniae*. *Antimicrob Agents Chemother* 2003; **47**: 77–81.

237. Takei M, Fukuda H, Kishii R, Hosaka M. Target preference of 15 quinolones against *Staphylococcus aureus*, based on antibacterial activities and target inhibition. *Antimicrob Agents Chemother* 2001; **45**: 3544–3547.

238. Akasaka T, Onodera Y, Tanaka M, Sato K. Cloning, expression, and enzymatic characterization of *Pseudomonas aeruginosa* topoisomerase IV. *Antimicrob Agents Chemother* 1999; **43**: 530–536.

239. Morrissey I, George J. Activities of fluoroquinolones against *Streptococcus pneumoniae* type II topoisomerases purified as recombinant proteins. *Antimicrob Agents Chemother* 1999; **43**: 2579–2585.

240. Yague G, Morris JE, Pan XS, Gould KA, Fisher LM. Cleavable-complex formation by wild-type and quinolone-resistant *Streptococcus pneumoniae* type II topoisomerases mediated by gemifloxacin and other fluoroquinolones. *Antimicrob Agents Chemother* 2002; **46**: 413–419.

241. Kahlmeter G, Brown DF, Goldstein FW *et al.* European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria. *J Antimicrob Chemother* 2003; **52**: 145–148.

242. Decousser JW, Allouch PY, Courvalin P, Leclercq R. In vitro activity of moxifloxacin against recent community-acquired respiratory tract pathogens isolated in France: a national survey. *Int J Antimicrob Agents* 2002; **20**: 186–195.

243. Ball P, Mandell L, Niki Y, Tillotson G. Comparative tolerability of the newer fluoroquinolone antibacterials. *Drug Safety* 1999; **21**: 407–421.

244. Ferguson J. Phototoxicity due to fluoroquinolones. In: Hooper DC, Rubinstein E, eds. *Quinolone antimicrobial agents*. Washington, DC: ASM Press, 2003; 451–460.

245. Burdge DR, Nakielna EM, Rabin HR. Photosensitivity associated with ciprofloxacin use in adult patients with cystic fibrosis. *Antimicrob Agents Chemother* 1995; **39**: 793.

246. Anonymous. Gemifloxacin. Factive, LB 20304, SB 265805. *Drugs Res Dev* 2002; **3**: 258–270.

247. Pertuiset E, Lenoir G, Jehanne M, Douchain F, Guillot M, Menkes CJ. Joint tolerance of pefloxacin and ofloxacin in children and adolescents with cystic fibrosis. *Rev Rhum Mal Osteoartic* 1989; **56**: 735–740.

248. Jick S. Ciprofloxacin safety in a pediatric population. *Pediatr Infect Dis J* 1997; **16**: 130–133.

249. Saint F, Salomon L, de la Cicco ATA, Chopin D, Abbou CC. Tendinopathy associated with fluoroquinolones: individuals at risk, incriminated physiopathologic mechanisms, therapeutic management. *Prog Urol* 2001; **11**: 1331–1334.

250. Pierfitte C, Royer RJ. Tendon disorders with fluoroquinolones. *Therapie* 1996; **51**: 419–420.

251. Kahn MF. Achilles tendinitis and ruptures. *Br J Sports Med* 1998; **32**: 266.

252. Khaliq Y, Zhanel GG. Fluoroquinolone-associated tendinopathy: a critical review of the literature. *Clin Infect Dis* 2003; **36**: 1404–1410.

253. Stahlmann R. Effects on connective tissue structures. In: Hooper DC Rubinstein E, eds. *Quinolone antimicrobial agents*. Washington, DC: ASM Press, 2003; 441–449.

254. Stahlmann R, Lode H. Fluoroquinolones in the elderly: safety considerations. *Drugs Aging* 2003; **20**: 289–302.

255. Norrby R. Central nervous system toxicity. In: Hooper DC, Rubinstein E, eds. *Quinolone antimicrobial agents*. Washington, DC: ASM Press, 2003; 461–465.

256. Stahlmann R. Clinical toxicological aspects of fluoroquinolones. *Toxicol Lett* 2002; **127**: 269–277.

257. Bowie WR, Willetts V, Jewesson PJ. Adverse reactions in a dose-ranging study with a new long-acting fluoroquinolone, fleroxacin. *Antimicrob Agents Chemother* 1989; **33**: 1778–1782.

258. Yap YG, Camm AJ. QT prolongation with quinolone antibacterial agents. In: Hooper DC, Rubinstein E, eds. *Quinolone antibacterial agents*. Washington, DC: ASM Press, 2003; 421–440.

259. Hurst M, Lamb HM, Scott LJ, Figgitt DP. Levofloxacin: an updated review of its use in the treatment of bacterial infections. *Drugs* 2002; **62**: 2127–2167.

260. Ball P, Mandell L, Patou G, Dankner W, Tillotson G. A new respiratory fluoroquinolone, oral gemifloxacin: a safety profile in context. *Int J Antimicrob Agents* 2004; **23**: 421–429.

261. Lode H, Rubinstein E. Adverse effects. In: Hooper DC, Rubinstein E, eds. *Quinolone antimicrobial agents*. Washington, DC: ASM Press, 2003; 407–419.

262. Bertino J, Fish D. The safety profile of the fluoroquinolones. *Clin Ther* 2000; **22**: 798–817.

263. Friedrich LV, Dougherty R. Fatal hypoglycemia associated with levofloxacin. *Pharmacotherapy* 2004; **24**: 1807–1812.

264. Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH. Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents. *Am J Med* 2002; **113**: 232–234.

265. Amankwa K, Krishnan SC, Tisdale JE. Torsades de pointes associated with fluoroquinolones: importance of concomitant risk factors. *Clin Pharmacol Ther* 2004; **75**: 242–247.

266. Corrao G, Botteri E, Bagnardi V *et al.* Generating signals of drug-adverse effects from prescription databases and application to the risk of arrhythmia associated with antibacterials. *Pharmacoepidemiol Drug Safety* 2005; **14**: 31–40.

267. Nicolle LE. Quinolones in the aged. *Drugs* 1999; **58**(suppl 2): 49–51.

268. Gendrel D, Moulin F. Fluoroquinolones in paediatrics. *Paediatr Drugs* 2001; **3**: 365–377.

269. Zhanel GG, Noreddin AM. Pharmacokinetics and pharmacodynamics of the new fluoroquinolones: focus on respiratory infections. *Curr Opin Pharmacol* 2001; **1**: 459–463.

270. Vogel F. Intravenous/oral sequential therapy in patients hospitalised with community-acquired pneumonia: which patients, when and what agents? *Drugs* 2002; **62**: 309–317.

271. Ball P, Mandell L. Treatment of community-acquired infections. In: Hooper DC, Rubinstein E, eds. *Quinolone antimicrobial agents*. Washington, DC: ASM Press, 2003; 227–243.

272. Rubinstein E. Fluoroquinolones in intensive care unit infections. In: Hooper DC, Rubinstein E, eds. *Quinolone antimicrobial agents*. Washington, DC: ASM Press, 2003; 337–342.

273. Karchmer AW. Fluoroquinolone treatment of skin and skin structure infections. *Drugs* 1999; **58**(suppl 2): 82–84.

274. Karchmer AW. Treatment of skin and soft tissue infections. In: Hooper DC, Rubinstein E, eds. *Quinolone antimicrobial agents*. Washington, DC: ASM Press, 2003; 311–321.

275. Bernard L, Waldvogel F, Lew D. Treatment of osteomyelitis and septic arthritis. In: Hooper DC, Rubinstein E, eds. *Quinolone antimicrobial agents*. Washington, DC: ASM Press, 2003; 251–258.

276. Solomkin JS. Treatment of intra-abdominal infections. In: Hooper DC, Rubinstein E, eds. *Quinolone antimicrobial agents*. Washington, DC: ASM Press, 2003; 217–226.

277. Bennish ML. Treatment and prophylaxis of gastro-enteritis. In: Hooper DC, Rubinstein E, eds. *Quinolone antimicrobial agents*. Washington, DC: ASM Press, 2003; 193–216.

278. Ronald A. The quinolones and renal infection. *Drugs* 1999; **58**(suppl 2): 96–98.

279. Wagenlehner FM, Naber KG. Fluoroquinolone antimicrobial agents in the treatment of prostatitis and recurrent urinary tract infections in men. *Curr Urol Rep* 2004; **5**: 309–316.

280. Skerk V, Schonwald S, Krhen I *et al.* Comparative analysis of azithromycin and ciprofloxacin in the treatment of chronic prostatitis caused by *Chlamydia trachomatis*. *Int J Antimicrob Agents* 2003; **21**: 457–462.

281. Dan M. The use of fluoroquinolones in gonorrhoea: the increasing problem of resistance. *Expert Opin Pharmacother* 2004; **5**: 829–854.

282. Tunkel AR, Scheld WM. Treatment of bacterial meningitis and other central nervous system infections. In: Hooper DC, Rubinstein E, eds. *Quinolone antimicrobial agents*. Washington, DC: ASM Press, 2003; 275–289.

283. Lesher GY, Gruett MD. Substituted 4-oxo-1,8-naphthyridines and intermediates. Belgian patent no. BE 612258. Assigned to: Sterling Drug Inc. 1962.

284. Deitz WH, Bailey JH, Froelich EJ. In vitro antibacterial properties of nalidixic acid, a new drug active against Gram-negative organisms. *Antimicrob Agents Chemother* 1963; **161**: 583–587.

285. Anonymous. Substituted quinolinecarboxy acid. Belgian patent no. BE 870917. Assigned to: Kyorin Pharmaceutical Co. Ltd Japan. 1979.

286. Ito A, Hirai K, Inoue M *et al.* In vitro antibacterial activity of AM-715, a new nalidixic acid analog. *Antimicrob Agents Chemother* 1980; **17**: 103–108.

287. Khan MY, Siddiqui Y, Gruninger RP. Comparative in vitro activity of Mk-0366 and other selected oral antimicrobial agents against *Neisseria gonorrhoeae*. *Antimicrob Agents Chemother* 1981; **20**: 265–266.

288. Goueffon Y, Montay G, Roquet F, Pesson M. A new synthetic antibacterial: 1-ethyl-6-fluoro-7-(4-methyl-1-piperazinyl)-4-oxo-1, 4-dihydroquinolin-3-carboxylic acid (1589 R.B.). *C R Seances Acad Sci III* 1981; **292**: 37–40.

289. Pesson M. 7-Dialkylamino-6-halo-4-oxo-1,4-dihydro-3-quinolinecarboxylic acids. German patent no. DE 2840910 197919790405. 1979.

290. Hirose T, Okezaki E, Kato H, Ito Y, Inoue M, Mitsuhashi S. In vitro and in vivo activity of NY-198, a new difluorinated quinolone. *Antimicrob Agents Chemother* 1987; **31**: 854–859.

291. Itoh Y, Kato H, Ogawa N, Koshinaka E, Suzuki T, Yagi N. 6-Fluoro-1,4-dihydro-4-oxo-7-(substituted piperazinyl) quinoline-3-carboxylic acid derivatives. German patent

no. DE 3433924. Assigned to: Hokuriku Pharmaceutical Co. Ltd, Japan. 1985.

292. Bauernfeind A, Petermuller C. In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid. *Eur J Clin Microbiol* 1983; **2**: 111–115.

293. Wise R, Andrews JM, Edwards LJ. In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents. *Antimicrob Agents Chemother* 1983; **23**: 559–564.

294. Grohe K, Zeiler HJ, Metzger K. 1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-piperazinoquinoline-3-carboxylic acids and an antibacterial agent containing them. German patent no. DE 3142854. Assigned to: Bayer A.-G. Fed. Report Ger. 1983.

295. Sato K, Matsuura Y, Inoue M *et al.* In vitro and in vivo activity of DL-8280, a new oxazine derivative. *Antimicrob Agents Chemother* 1982; **22**: 548–553.

296. Hayakawa I, Tanaka Y, Hiramitsu T. Benzoxazine derivatives. Eur. Pat. Appl. patent no. EP 47005. Assigned to: Daiichi Seiyaku Co. Ltd Japan. 1982.

297. Hayakawa I, Atarashi S, Yokohama S *et al.* Optically active (S)-(–)-pyridobenzoxazinecarboxylate derivatives, their intermediates, use as antimicrobials. Eur. Pat. Appl. patent no. EP 206283. Assigned to: Daiichi Seiyaku Co. Ltd, Japan. 1986.

298. Hayakawa I, Atarashi S, Yokohama S, Imamura M, Sakano K, Furukawa M. Synthesis and antibacterial activities of optically active ofloxacin. *Antimicrob Agents Chemother* 1986; **29**: 163–164.

299. Nakamura S, Minami A, Nakata K *et al.* In vitro and in vivo antibacterial activities of AT-4140, a new broad-spectrum quinolone. *Antimicrob Agents Chemother* 1989; **33**: 1167–1173.

300. Matsumoto J, Miyamoto T, Egawa H, Nakamura S. Preparation of piperazinylquinolonecarboxylates as bactericides. Eur. Pat. Appl. patent no. EP 221463. Assigned to: Dainippon Pharmaceutical Co. Ltd, Japan. 1987.

301. Imada T, Miyazaki S, Nishida M, Yamaguchi K, Goto S. In vitro and in vivo antibacterial activities of a new quinolone, OPC-17116. *Antimicrob Agents Chemother* 1992; **36**: 573–579.

302. Ueda H, Miyamoto H, Yamashita H, Tone H. Preparation of quinolinonecarboxylates as bactericides. Eur. Pat. Appl. patent no. EP 287951. Assigned to: Otsuka Pharmaceutical Co. Ltd, Japan. 1988.

303. Hosaka M, Yasue T, Fukuda H, Tomizawa H, Aoyama H, Hirai K. In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone. *Antimicrob Agents Chemother* 1992; **36**: 2108–2117.

304. Iwata M, Kimura T, Fujiwara Y, Katsube T. Preparation of alkoxyfluoroquinolonecarboxylic acid derivatives as medical bactericides. Eur. Pat. Appl. patent no. EP 241206. Assigned to: Sankyo Co. Ltd, Ube Industries Ltd, Japan. 1987.

305. Gooding BB, Jones RN. In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone. *Antimicrob Agents Chemother* 1993; **37**: 349–353.

306. Brighty KE. Preparation of azabicycloalkylquinolones and -naphthyridinones as antibacterials. US patent no. US 5164402 (abandoned). Assigned to: Pfizer Inc., USA. 1992.

307. Dalhoff A, Petersen U, Endermann R. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone. *Chemotherapy* 1996; **42**: 410–425.

308. Petersen U, Krebs A, Schenke T *et al.* Preparation of (diazabicyclononyl) quinolones and related compounds as antibacterials. Eur. Pat. Appl. patent nno. EP 550903. Assigned to: Bayer A.-G., Germany. 1993.

309. Oh JI, Paek KS, Ahn MJ *et al.* In vitro and in vivo evaluations of LB20304, a new fluoronaphthyridone. *Antimicrob Agents Chemother* 1996; **40**: 1564–1568.

310. Kwak JH, Jeong YN, Oh JI. Preparation of novel 7-[(4-aminomethyl-3-alkoxyimino)pyrrolidin-1-yl]quinoline-3-carboxylic acid derivatives as antibacterial agents. Eur. Pat. Appl. patent no. EP 688772. Assigned to: LG Chemical Ltd, South Korea. 1995.

311. Takahata M, Mitsuyama J, Yamashiro Y *et al.* In vitro and in vivo antimicrobial activities of T-3811ME, a novel des-F(6)-quinolone. *Antimicrob Agents Chemother* 1999; **43**: 1077–1084.

312. Todo Y, Hayashi K, Takahata M, Watanabe Y, Narita H. Preparation of quinolonecarboxylic acid derivatives as antibiotics. PCT Int. Appl. patent no. WO 9729102. Assigned to: Toyama Chemical Co. Ltd, Japan. 1997.